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A PERSPECTIVE ON THE SCIENTIFIC, PHILOSOPHICAL, AND POLICY
DIMENSIONS OF HORMESIS
George R. Hoffmann  Department of Biology, College of the Holy Cross,
Worcester, MA
 The hormesis concept has broad implications for biology and the biomedical sciences.
This perspective on hormesis concentrates on toxicology and toxicological risk assessment
and secondarily explores observations from other fields. It considers the varied manifes-
tations of hormesis in the context of a broad family of biological stress responses. Evidence
for hormesis is reviewed, and the hormesis model is contrasted with more widely accept-
ed dose-response models in toxicology: a linear nonthreshold (LNT) model for mutagen-
esis and carcinogenesis, and a threshold model for most other toxicologic effects.
Scientific, philosophical, and political objections to the hormesis concept are explored,
and complications in the hormesis concept are analyzed. The review concludes with a per-
spective on the current state of hormesis and challenges that the hormesis model poses
for risk assessment.
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DOSE-RESPONSE MODELS FOR EFFECTS AT LOW DOSES
Three models have dominated thinking about effects of exposures to
low doses of toxicants and radiation: a threshold model, a linear model
with no threshold (LNT), and a hormetic model. The threshold model is
widely considered to be the standard in toxicology, except that LNT pre-
vails in mutagenesis and carcinogenesis. Hormesis, which entails a bipha-
sic dose-response, is a challenge to the threshold and LNT models
(Calabrese and Baldwin 2001a, 2003a, 2003b; Calabrese and Blain 2005).
Figure 1 shows dose-response relationships representing the three
models. The threshold model (Figure 1A) has a classical NOAEL (no
observed adverse effect level) or a true threshold below which there is no
effect. When expressed for a quantal characteristic in a finite population,
the threshold model takes the form of the classic sigmoid curve shown in
essentially all toxicology textbooks (Eaton and Gilbert 2008). The thresh-
old model is considered a basic principle of toxicology, despite the fact
that its predictions about low doses are based heavily on theory and
assumptions. Mutagenesis and carcinogenesis differ from most of toxi-
cology, in that the prevailing assumption has been low-dose linearity,
reflected in the LNT model (Figure 1B). The LNT model has a linear
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decline in adverse effect with decreasing dose down to the spontaneous
frequency, such that all doses are considered to have an effect. Hormesis
is described by a dose-response curve with effects at low doses opposite to
those at high doses (Figure 1C). Thus, the hormetic curve is nonmonot-
onic, such that the dependent variable—response—changes in more
than one direction with a unidirectional change in the independent vari-
able—dose (Davis and Svendsgaard 1994). In contrast, the threshold and
linear models are monotonic, showing an increase or decrease in biolog-
G. R. Hoffmann
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FIGURE 1. Three dose-response models: (A) threshold model; (B) linear model; (C) hormesis
model. The curves compare responses to the spontaneous frequency of the toxicologic effect being
measured. A NOAEL (no observed adverse effect level) and ZEP (zero equivalent point) are shown
for the threshold and hormesis models. The figure is adapted from Hoffmann and Stempsey 2008.
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ical response over the entire range of doses that have an effect. The
biphasic hormetic curve is often described as J-shaped or U-shaped (Davis
and Svendsgaard 1994; Calabrese 2002; Conolly and Lutz 2004). It shows
a zero equivalent point (ZEP), which is a variation on the concept of a
NOAEL befitting the hormesis concept, in that it does not imply a thresh-
old in the classical sense.
The dominance of the LNT model in mutagenesis and carcinogenesis
stems from target theory, early observations at moderate to high doses that
were consistent with linearity, and the historical roots of these fields
(Auerbach 1976; National Research Council 1980, 2006; Brenner et al.
2003; Brenner and Sachs 2006; Friedl and Rühm 2006). The induction of
mutations by ionizing radiation, discovered by H.J. Muller in 1927 (Muller
1927), remained a model for understanding mutagenesis even after the
burgeoning of research in chemical mutagenesis after World War II.
Chemical mutagenesis was in many ways the offspring of radiation biolo-
gy, which shaped the way that geneticists viewed mutagenesis in general. If
mutations resulted from a direct interaction between the mutagen and its
target, DNA, following one-hit kinetics, one should expect linearity
(Auerbach 1976). While there are exceptions, early studies of mutagene-
sis were largely compatible with this expectation (Friedl and Rühm 2006).
An interesting historical note is that Charlotte Auerbach, who, togeth-
er with J.M. Robson, discovered chemical mutagenesis through work with
mustard gas in Drosophila during World War II (Auerbach and Robson
1946, 1947), argued clearly in her 1976 book “Mutation Research: Problems,
Results, and Perspectives” that mutagenesis is a complex cellular process,
involving the processing of lesions by organisms, not a unitary interaction
between mutagen and target (Auerbach 1976). Although the correctness
of her argument was clear to most workers in chemical mutagenesis, it has
taken time to shake the foundation of an expectation of linearity.
Increasing awareness of the complexity of mutagenesis as a biological
process and the diversity of its mechanisms has led to growing receptive-
ness to nonlinear dose-response relationships and thresholds, even for
such mutagens as alkylating agents that are a model of direct mutagen-
DNA interaction (Kodell 2001; Bolt et al. 2004; Fukushima et al. 2005;
Jenkins et al. 2005). Factors in mutagenesis include the uptake and
metabolism of mutagens, direct and indirect interactions between muta-
gen and DNA, recognition and processing of damage by enzymes of
repair and recombination, influences of cellular proliferation and apop-
tosis, and conditions for mutant expression. These introduce many possi-
bilities for deviations from linearity. Thus, mutagenesis should be consid-
ered an integral part of the spectrum of biological effects of toxicants and
radiation, not an effect requiring fundamentally different expectations.
The somatic mutation theory of cancer became established early in
the twentieth century, having been espoused by one of the founders of
Perspective on hormesis
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the Chromosome Theory of Inheritance, Theodor Boveri, between 1902
and 1914 (Boveri 1929; reviewed in Manchester 1995). Given the many
linkages between mutagenesis and carcinogenesis, it was natural to think
that what is true of one should be true of the other. When one concen-
trates on doses for which responses are readily measured—that is, higher
doses—results in radiation carcinogenesis are largely compatible with the
expectation for linearity (Brenner et al. 2003; Redpath et al. 2003a;
Redpath 2006). Even at low doses, epidemiology may not detect U-shaped
curves or other deviations from linearity because modest responses
merge with random variation, and many studies are affected by mixed
qualities of radiation and the pooling of different endpoints (Redpath et
al. 2003a). Therefore, the LNT model has persisted, resting heavily on
observations at higher doses combined with its theoretical foundation
(Brenner and Sachs 2006).
LNT remains the dominant model in radiation risk assessment, as is
reflected in the latest report of the U.S. National Academy of Sciences
(NAS) on ionizing radiation (National Research Council 2006). However,
the debate has intensified in light of evidence contrary to LNT, both from
epidemiologic findings and from studies of carcinogenesis and longevity
in laboratory animals (Duport 2003; Tubiana and Aurengo 2006; Tubiana
et al. 2006). The recent Joint Report of the French Academies reached a
decidedly different conclusion from the NAS, rejecting LNT as a realistic
model for low doses of ionizing radiation (Aurengo et al. 2005; Tubiana
and Aurengo 2006; Tubiana et al. 2006).
The French report, which shows receptiveness to the concept of radi-
ation hormesis, holds that LNT is apt to strongly overestimate the car-
cinogenic effects of doses below ~100 mSv, and the overestimation is
undoubtedly much greater at very low doses (<10 mSv) (Tubiana et al.
2006). Expecting linearity for carcinogenicity is questionable because of
the diversity of mechanisms by which genotoxic and nongenotoxic car-
cinogens induce cancer. Epigenetic processes are important in carcino-
genesis, and the outcome is modulated by such factors as cell prolifera-
tion, repair, apoptosis, intercellular communication, and cell signaling
(Klaunig et al. 2000; Fukushima et al. 2005; Kinoshita et al. 2006). The
process is far removed from the unitary interaction between agent and
target envisioned in hit theory. Receptiveness to nonlinearity in carcino-
genesis has therefore grown, especially for carcinogens with a nongeno-
toxic mode of action, but also for agents that act through genotoxic
mechanisms (Kodell 2001).
DEFINING HORMESIS
Hormesis has been defined on different grounds, and this fact has
undoubtedly contributed to confusion as to the nature of the concept.
Most basically, hormesis is a dose response relationship in which effects at
G. R. Hoffmann
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low doses are opposite to those at high doses. As a consequence, hormet-
ic dose response curves are biphasic rather than being monotonic. The
biphasic curve is so central that hormesis is often defined with respect to
a dose-response curve that is essentially J-shaped or an inverted U (Davis
and Svendsgaard 1990; Calabrese and Baldwin 2002a).
J-shaped and inverted-U biphasic curves
Figure 2 shows “J-shaped” and “inverted-U” curves typical of hormesis.
The effect on the ordinate of the J-shaped curve is some dysfunction, such
as carcinogenesis, with the spontaneous level of the event denoted by a
horizontal line. The hormetic zone shows a frequency less than that occur-
ring spontaneously with no exposure. If the endpoint were a normal bio-
logical function, such as growth, the hormetic curve would appear as an
inverted U, in which the hormetic zone is represented by effects above the
background level and the toxic zone by effects below it (Calabrese and
Baldwin 2003c; Hoffmann and Stempsey 2008). Terms that have been
used to describe U- or J- shaped curves include hormesis, β-curve, bell-
shaped, biphasic, diphasic, bitonic, bidirectional, sinusoidal, subsidy gra-
dient, functional antagonism, dual response, nonmonotonic, and stimula-
tory-inhibitory (Calabrese and Baldwin 2002a; Calabrese et al. 2007).
Biological stress responses, adaptive response, and preconditioning
Besides its biphasic nature, hormesis may be defined on the basis of
evolutionarily conserved biological responses to stress (Calabrese et al.
2007). Stress responses are processes by which a small exposure to a stress-
ful stimulus (e.g., a low dose) increases the resistance of the cell or organ-
ism to a moderate or severe level of stress (Arumugam et al. 2006). The
relationship of hormesis to stress responses was foreseen by T.D. Luckey
who proposed in 1968 that “subharmful quantities of any stressing agent
Perspective on hormesis
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FIGURE 2. Dose-response curve showing hormesis in the form of a J-shaped curve and an inverted-U
curve. In the former the effect on the ordinate is a biological dysfunction, such as carcinogenicity or
any other indicator of toxicity. In the latter, the response is a normal biological function such as growth.
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will be stimulatory to the organism” (Luckey 1968). Through the years,
different terminology has come into use to describe different aspects of a
family of related biological responses, including hormesis, precondition-
ing, and adaptive response (Calabrese et al. 2007; Calabrese 2008a).
Among the agents that induce stress responses are toxicants, heat, hypox-
ia, caloric restriction, metabolic products, oxidants, and ionizing radiation
(Wolff 1989; Miura 2004; Calabrese et al. 2007; Rattan 2008). Such
responses are phylogenetically widespread, occurring in prokaryotes,
fungi, plants, and animals (Miura 2004; Calabrese et al. 2007).
A feature that distinguishes adaptive responses and preconditioning
from hormesis as originally defined is that the latter occurs at low doses
without dependence on an earlier exposure (Calabrese et al. 2007).
Adaptive responses and preconditioning have also been called xeno-
hormesis, autoprotection, and heteroprotection, the latter being distin-
guished by cross-resistance to agents other than the inducer itself
(Calabrese et al. 2007). Because of their historical origins, hormetic
responses have also been referred to as the Arndt-Schulz Law, Hueppe’s
Rule, and the Yerkes-Dodson Law (Calabrese et al. 2007). A group of over
50 scientists recently made recommendations to achieve greater concep-
tual coherence in dose-response terminology and better interdisciplinary
communication (Calabrese et al. 2007). The proposed terminology uses
prefixes to identify the inducing agent (chemical, radiation, or physio-
logical stress) and to distinguish whether a prior exposure is involved.
Examples include radiation hormesis, radiation conditioning hormesis,
chemical hormesis, and physiological conditioning hormesis.
Stress responses are commonly called an adaptive response in genet-
ics (Jeggo et al. 1977; Cairns 1980; Wolff 1998; Mitchel et al. 2004; Chen
et al. 2006a) and preconditioning in other areas of biomedical sciences
(Murry et al. 1986; Arumugam et al. 2006; Calabrese et al. 2007; Lin et al.
2008). An adaptive response refers to a phenomenon whereby a small
dose of a toxicant or radiation renders cells or organisms less susceptible
to effects of a subsequent larger dose. The first adaptive response was dis-
covered in E. coli, where the methylating agent N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG) was found to have a smaller mutagenic effect
if the bacteria had previously been exposed to a low dose of the same
agent (Samson and Cairns 1977; Jeggo et al. 1977). The rate of arg rever-
sion in E. coli strain AB1157 was about 6000-fold higher in an ada5 mutant
that lacks the adaptive response (Cairns 1980). The adaptive response
also confers resistance to other alkylating agents that operate by a similar
mechanism; it involves more rapid repair of the premutational lesion O6-
methylguanine in the exposed cells (Cairns 1980; Volkert 1988; Shevell et
al. 1990; Kleibl 2002). The finding in bacteria was extended to mam-
malian cells, where chronic treatment with MNNG rendered the cells less
susceptible to the induction of sister chromatid exchange by higher doses
of MNNG (Samson and Schwartz 1980). Adaptive responses have also
G. R. Hoffmann
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been characterized for agents that cause oxidative damage in bacteria
(Demple and Halbrook 1983; Winquist et al. 1984; Christman et al. 1985;
vanBogelen et al. 1987), yeast (Davies et al. 1995), and mammalian cells
(Wiese et al. 1995; Chen et al. 2006a). 
Ionizing radiation induces an adaptive response in mammalian cells
(Wolff et al. 1988; Wolff 1998). Exposure to low doses of low linear-ener-
gy-transfer (LET) radiation (0.5-2 cGy x rays) makes the cells less suscep-
tible to the induction of chromosomal damage by larger doses of either
low-LET (Shadley and Wolff 1987; Shadley et al. 1987) or high-LET (α
particle) radiation (Wolff et al. 1993). Studies in which damage was
induced by restriction enzymes showed that double-strand breaks in DNA
trigger the adaptive response (Wolff 1998). Low doses of radiation can
also alter susceptibility to genotoxic and carcinogenic effects of chemi-
cals, depending on the nature of the lesions induced and their intracel-
lular processing. For example, γ-radiation was observed to reduce the
clastogenic effects of bleomycin and mitomycin C in human lymphocytes
but to increase their susceptibility to methyl methanesulfonate (Wolff et
al. 1988), and extended exposure to γ-radiation at a low dose-rate (1.2
mGy / h) suppressed the skin carcinogenicity of 3-methylcholanthrene in
mice (Sakai et al. 2006).
Thus, diverse agents are involved in adaptive responses, both as
inducers and as agents protected against (Wolff et al. 1988; Wolff 1989;
Ishii and Watanabe 1996; Mitchel 2006; Calabrese et al. 2007). The dif-
ferent adaptive responses have distinctive attributes and specificities, yet
they share some overlapping components and functions (vanBogelen et
al. 1987; vanBogelen and Neidhardt 1990; Miura 2004; Seo et al. 2006).
They encompass diverse biological endpoints (Mitchel 2006; Seo et al.
2006; Calabrese et al. 2007). Adaptive responses have been studied most
extensively in cell cultures and microorganisms, but they have also been
reported in mammals in vivo (Kang et al. 2002; Mitchel et al. 2003, 2004;
Sakai et al. 2006; Mitchel 2006, 2007), including effects on germ-cell
mutagenesis (Boreham et al. 2006; Mitchel 2006).
A stress response called preconditioning, conceptually similar to the
adaptive response, was first described by Murry et al. in 1986. Through
experiments in dogs, they found that brief exposures to hypoxia resulting
from mild coronary occlusion reduced the severity of myocardial infarc-
tion caused by a subsequent longer episode of coronary occlusion (Murry
et al. 1986). Similar observations have since been made for other species
and organ systems (Calabrese et al. 2007; Lin et al. 2008).
Relationship to the concepts of NOEL, NOAEL, and ZEP
The relationship of hormesis to the concepts of a NOEL (no
observed effect level), NOAEL (no observed adverse effect level), and
zero equivalent point (ZEP) warrants consideration. A NOEL holds that
Perspective on hormesis
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there is a dose below which there is no effect, an assumption that fits a
threshold model. A NOAEL can fit either a threshold model or a hormet-
ic model depending on whether lower doses have no effect or effects
opposite to those of high doses. The ZEP has been defined for hormetic
curves as a point that is equivalent to the control (Calabrese 2005a). As
such, it is essentially equivalent to the NOAEL, but it can be useful con-
ceptually, in that NOAEL includes “adverse” and can be confused with
NOEL, while the ZEP only states that the curve reaches the control level
at this point. A biphasic curve arises from responses above and below the
ZEP being on opposite sides of the control or background level. Thus, the
designation of a ZEP is well suited to the hormesis concept. Unlike a
NOEL, it does not imply a threshold model, and unlike a NOAEL, it
excludes “adverse” and is therefore neutral to notions of benefit and
harm.
Relationship to the prediction of low-dose effects
In suggesting a qualitative difference between responses at low doses
and those at high doses, the hormesis model runs counter to the assump-
tion that effects at low doses can be predicted from those at high doses in
a reasonably straightforward way. This often-unchallenged assumption is
a keystone in risk assessment because direct measurements may not
resolve what actually happens at low doses. Biological effects at extreme-
ly low doses are not readily measured experimentally or epidemiological-
ly (Redpath et al. 2003a; Redpath 2006), and low-dose data are often com-
patible with more than one of the three basic models. Monotonic curves,
whether linear or nonlinear, have the appealing feature of getting around
this problem by substituting prediction for measurability. Loss of the
assumption that high-dose responses can predict those at low doses would
make risk estimation more difficult. Biphasic curves do not necessarily
exclude the possibility of predicting low-dose effects, in that one could, in
principle, extrapolate on the basis of a hormetic curve if the features of
hormesis were quantitatively consistent and known. Moreover, in point-
ing out qualitative differences between the different parts of a dose-
response curve, biphasic curves can highlight important responses that
may otherwise be overlooked.
DEFAULT ASSUMPTIONS, BENEFIT, AND HARM
Whether a threshold model, LNT, or a hormetic model can serve as
a default model for effects at low doses is controversial. In its simplest
form, a “default” model refers to the most reasonable expectation for
responses at low doses when there is insufficient evidence to know what
actually happens in the low-dose range. To be used as a surrogate for low-
G. R. Hoffmann
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dose data in risk assessment, one needs strong evidence that the model is
generalizable, reliable, and quantitatively predictive of the specific bio-
logical response of interest for which data are unavailable (Calabrese
2004; Mushak 2007). A default model is typically driven by theory that
explains the totality of the curve, such as target theory in the case of LNT,
and by experimental evidence albeit with limited power at low doses. The
kind of response predicted by a model would need to be highly prevalent
for the model to qualify as a default assumption (Crump 2001).
Unfortunately, discussions of default assumptions sometimes leave
vague whether the model is intended to shape expectations for the scien-
tific interpretation of low doses or to define risks and allowable exposures.
Striving for conservatism is common in risk assessment, in accordance
with the view that it is better to overestimate risk than to underestimate it
(National Research Council 1980). While the correctness of the model is
essential for scientific purposes, it may be less so for the purposes of poli-
cy. One could conceivably favor hormesis as a default assumption for sci-
entific interpretation of low-dose effects but accept an LNT or a threshold
model for risk assessment related to public policy. Such a dichotomy,
although defensible, has pitfalls, including adverse effects that may stem
from basing policy on something less than the best science available.
Discussions of hormesis are beset with difficulties owing to the failure
to separate the phenomenon from whether its effects are beneficial or
harmful. Because toxicologists and radiation biologists have historically
emphasized adverse effects at high doses, there is a tendency to assume
that hormesis means that low dosages are beneficial. Although sometimes
true, this extension of the definition of hormesis is an oversimplification.
If a low dose of an inhibitory drug stimulates a detrimental hyperplasia,
the hormetic zone would be detrimental. The disruption of endocrine
regulation has been identified as a case in which the high-dose and low-
dose zones of a biphasic curve may both be harmful, and studies of
bisphenol A, the monomer of polycarbonate plastic, have been cited in
support of this interpretation (vom Saal and Sheehan 1998; vom Saal and
Hughes 2005; Timms et al. 2005). If a high dose of a drug inhibits a par-
asite and a low dose stimulates it, the human benefit is associated with the
toxic zone, and we had better be aware of hormesis to avoid the hazard
of the hormetic zone. Focusing on the possibility of beneficial effects at
low doses has led some to oppose the hormesis concept because of a con-
cern that the recognition of hormesis may lead to a weakening of envi-
ronmental standards or public health protection (Axelrod et al. 2004).
Nevertheless, rigidly linking hormesis to benefit can undermine objective
inquiry. Nothing in the hormesis concept requires that hormetic effects
are beneficial. Hormesis is best defined on the basis of biological and
quantitative attributes, not benefit or harm (Stebbing 2000; Calabrese
and Baldwin 2002a; Calabrese 2008a).
Perspective on hormesis
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EVIDENCE FOR HORMESIS
The history of hormesis extends into the nineteenth century and has
been reviewed by Calabrese (Calabrese 2002, 2005b, 2008a). The modern
era of hormesis may be traced to a paper by Southam and Ehrlich (1943),
who coined the term “hormesis” to describe modest stimulatory effects of
extracts from western red-cedar heartwood on cultured fungi that were
strongly inhibited by high concentrations of the same extract. Despite its
long history, hormesis was not a serious consideration in toxicology
through much of the twentieth century for a combination of scientific and
historical reasons (Calabrese 2002, 2005b, 2008a). This began to change
in the 1980’s and 1990’s with recurring observations of hormetic effects,
surveys of scientific literature, and commentaries by scientists convinced
that these observations were important (Sagan 1989; Calabrese and
Baldwin 2001a, 2001b). The evidence that hormesis is real is now strong.
Hormesis is common in surveys of scientific literature. Over 45 years
ago, Townsend and Luckey (1960) examined the pharmacology litera-
ture for evidence of hormesis, defined as the “stimulatory action of a
subinhibitory amount” of a toxicant. They identified hormesis, which
they called hormoligosis, on the basis of a biphasic dose-response rela-
tionship, called a “β-pattern,” and they cited over 100 such responses
caused by diverse agents. A few decades later, the studies of toxicological
literature became more systematic in a survey by Davis & Svendsgaard
(1994) and culminated in the massive efforts of Calabrese and Baldwin
(2001a, 2001b, 2003a), who used carefully delineated criteria for choos-
ing papers for evaluation and found biphasic dose-response relationships
to be widespread. Roughly 3000 published examples of hormesis had
been reported by 2001 (Calabrese 2002; Calabrese and Baldwin 2001a,
2001b), and by 2005 the number had swelled to over 5500 dose-response
relationships (Calabrese and Blain 2005). A database of hormetic
responses encompasses phylogenetically diverse organisms, including
bacteria, fungi, plants, insects, fish, birds, and mammals, including
humans (Calabrese and Blain 2005). Both sexes and organisms of varied
ages are represented, and there are about 900 agents from diverse chem-
ical classes (Calabrese and Blain 2005). Besides studies in intact organ-
isms, hormetic effects are common in cultured mammalian cells, includ-
ing many tumor cell lines (Calabrese 2005a).
The analysis of data from systematic chemical testing provides strong
evidence of hormesis. The Developmental Therapeutics Program (DTP)
of the U.S. National Cancer Institute (NCI) has a longstanding program
of high-throughput screening of chemicals for toxicity in order to identi-
fy prospective cancer chemotherapy drugs (Holbeck 2004). Over 87,000
chemicals have been tested in yeast, of which 2189 compounds went from
preliminary screening into multiple-dose screening in 13 genetically dif-
G. R. Hoffmann
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ferent strains (Holbeck 2004). The responses were measures of yeast
growth in 12 h in 96-well plates, determined as optical densities, at each
of 5 concentrations (1.2, 3.7, 10, 33, 100 μM). Each OD value was
expressed as a ratio of the chemical well to the mean of 8 concurrent sol-
vent-control wells on the same plate. The determination was repeated on
another day, and the average of the two values was considered one repli-
cate. The NCI database reported the average of two replicates and the dif-
ference between them.
The NCI yeast data, comprising 56,914 dose responses, were analyzed
by Calabrese et al. (2006, 2008) to determine whether they are more com-
patible with hormesis or a threshold model. A Benchmark Dose (BMD),
roughly equivalent to a NOAEL or ZEP, was calculated as an estimate of
the minimum dose causing toxicity (Calabrese et al. 2006). If the thresh-
old model were correct, one would expect responses for doses below
those causing inhibition to be randomly distributed above and below the
control level. In contrast, one would expect a predominance of respons-
es greater than the control if hormesis were prevalent. Growth at doses
below the BMD was significantly greater than the control in all yeast
strains for both highly toxic compounds (low BMD) and relatively non-
toxic compounds (high BMD). The data for average growth are summa-
rized in Table 1. The fact that these responses are all over 100% of con-
trol growth can be ascribed to hormesis. The pattern of responses was
consistent with the hormetic model but not with the threshold model.
Hormetic response patterns occurred about four times more often than
expected by chance (Calabrese et al. 2006). Several different methods of
analysis were consistent with one another in showing that hormesis is
common in the yeast database (Calabrese et al. 2006, 2008).
Hormetic responses show descriptive and quantitative similarities
beyond the biphasic curve that suggest conceptual coherence. Analysis of
a database of over 5500 examples of hormetic inverted-U dose responses
(Calabrese and Blain 2005) showed that hormetic effects tend to be mod-
est, commonly differing from the control by 30-60% (Calabrese 2002,
2005a; Calabrese and Blain 2005; Calabrese 2008a). Thus, if differences
are twofold or more, one should suspect that something other than
hormesis is involved (Calabrese 2002). The hormetic zone occurs at
exposure levels immediately below the NOAEL, and its width is variable.
It extends to doses several-fold below the NOAEL, often 10- to 20-fold,
but only rarely approaches 100-fold (Calabrese 2002, 2005a; Calabrese
and Blain 2005). These patterns observed in the scientific literature are
also supported by an analysis of an NCI database on 136 human tumor
cell lines derived from over 30 tissues treated with 120 agents, including
antineoplastic drugs, other drugs, pollutants, endogenous agonists, and
plant compounds (Calabrese 2005a). 
Perspective on hormesis
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PHILOSOPHICAL QUESTIONS ABOUT HORMESIS
One may distinguish several bases for argument about hormesis:
philosophical questions related to the hormesis concept, scientific issues,
and controversial political or ethical issues. Philosophical objections to
hormesis center around the question of whether there is epistemological
warrant for the hormesis concept. Hormesis has diverse manifestations,
and these may obfuscate conceptual clarity.
Those skeptical of the existence of hormesis or of its implications have
argued that hormesis has suffered from the lack a stable definition, thus
creating confusion about what hormesis is (Elliott 2000, 2006; Mushak
2007). Elliott (2000) has argued that there are seven distinct concepts of
hormesis in the literature (Elliott 2000). He describes three of these as
operational, three mechanistic, and one adaptive. The operational con-
cepts are defined with respect to biological endpoints; the mechanistic
concepts focus on causal interactions among constituents of a system; and
the adaptive concept is a generalized response to biological stress. He con-
cludes that none of these is sufficient to provide epistemological warrant
for hormesis (Elliott 2000). Such taxonomic splitting may not be necessary
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TABLE 1. Mean percentage of control growth of yeast strains for chemical exposures below the
BMD: Values over 100% suggest hormesisa
Dosage Range of the BMDb
3.7-11 µM >100 µM
Strain (high toxicity) 11-33 µM 33-100 µM (low toxicity)
Wild type 102.6 107.2 105.8 105.1
SPY50780 106.1 108.3 108.8 105.5
CLN2oe 101.7 103.7 104.6 104.8
mgt1 102.7 106.6 106.5 105.0
mec2 105.4 107.3 105.8 106.0
mlh1 103.8 107.2 105.9 104.5
rad14 103.9 107.4 106.5 106.4
bub3 104.8 106.0 106.8 106.0
rad50EPP+ 102.2 105.3 106.3 107.7
sgs1 103.3 106.7 106.8 104.8
rad52 103.6 106.8 105.9 104.0
rad18 103.9 106.2 106.5 106.6
rad50 102.9 105.5 104.4 104.7
∑ (mean ± SEM)c 103.6 ± 0.18 106.6 ± 0.18 106.2 ± 0.20 105.5 ± 0.17
a Table based on Calabrese et al., 2006.
b All values are based on a BMD(10) as defined in Calabrese et al., 2006. Other BMD criteria (2.5,
5, 7.5, 12.5) support the same interpretations. The column for 3.7<BMD<11 is based on responses at
1.2 µM; 11<BMD<33 is based on 1.2 and 3.7 µM; 33<BMD<100 is based on 1.2, 3.7, and 11 µM; and
the BMD>100 column is based on responses at 1.2, 3.7, 11, and 33 µM.
c The average number of responses on which a single mean value is based is 402 (196-572 range).
The overall means are based on 5326, 6266, 4544, and 4763 responses for the four BMD ranges
shown left to right.
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for exploring the scientific basis for hormesis, but it does suggest that the
complexity of hormesis may hinder conceptual clarity. For policy purpos-
es, Elliott’s operational definitions, which center on the predictiveness of
outcomes for defined endpoints at low doses, may be most germane,
whereas the mechanistic concepts may be most fruitful for exploring the
basic nature of the phenomenon (Hoffmann and Stempsey 2008). 
If one takes the multifaceted nature of a concept as a philosophical
limitation, one might similarly raise doubts about other central biological
concepts. Evolution is the central paradigm of modern biology. As stated
famously by Theodosius Dobzhansky about 40 years ago, “Nothing in biol-
ogy makes sense except in the light of evolution” (Dobzhansky 1964).
One may define evolution in various ways and recognize it as a multifac-
eted phenomenon, yet this does not alter its essential truth as a phenom-
enon and its ability to explain diverse observations in the biological sci-
ences. A look at two well-known textbooks shows evolution to be defined
as “change in the genetic makeup of a population with time” (Keeton and
Gould 1986) or as “all the changes that have transformed life on Earth
from its earliest beginnings to the diversity that characterizes it today”
(Campbell et al. 1999). Evolution is a multifaceted concept (Kardong
2008), and one might distinguish at least three levels of discussion about
it: 1) the fact of evolution—evidence that organisms change through
time; 2) phylogeny, the historical course of evolution; and 3) mechanisms
of evolution—Darwinian natural selection and other elements, including
mutation, chromosomal alterations, and random changes in the genetic
structure of populations. There is no informed disagreement about the
first, but debate continues among evolutionary biologists concerning the
second and third.
The parallel between evolution and hormesis leads me to discount
arguments that the multifaceted nature of hormesis undermines its epis-
temological justification (Elliott 2000). Some concession should be made,
however, that clarity about the meaning of hormesis is essential. If we are
thinking of hormesis in the narrow sense of a biphasic dose response, we
should be explicit about this, just as we should be explicit when we are
using hormesis in the broad sense of a family of stress responses that man-
ifest themselves in diverse ways. For the purposes of policy related to tox-
icology, the operational definitions of hormesis—centered squarely on
the biphasic dose response—have the most central importance.
SCIENTIFIC ISSUES GENERATING DEBATE ABOUT HORMESIS
The first question that one may ask about hormesis is whether it is
real. An accumulation of evidence calls for an affirmative answer.
Questions that continue to generate debate about hormesis center
around impediments to detecting hormesis, artifacts that resemble
hormesis, difficulties in evaluating the prevalence of hormesis from sci-
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entific literature, the paucity of experiments specifically designed to study
hormesis, and insufficient understanding of mechanisms.
Impediments to detecting and measuring hormesis
Most scientific objections to hormesis stem from its being a low-dose
phenomenon. Toxicology is centered on studying adverse effects, and
this led to a focus on high doses where toxic responses are readily detect-
ed and measured. If preliminary experiments include low doses, these
are commonly underrepresented in follow-up studies where adverse
effects are of interest. Even if a study includes low doses, unequivocal evi-
dence of hormesis may be elusive because of a lack of statistical power.
Hormetic effects tend to be modest, and differences from background
levels of the biological effect are small (Calabrese and Baldwin 2001b;
Calabrese 2003). Without systematic analysis of large data sets or large
experiments with multiple sub-NOAEL doses, hormetic effects are com-
monly ascribed to random variation. Data that appear to be hormetic do
not necessarily exclude other models.
Even studies conducted on a large scale to increase the power to
detect small differences can be consistent with several models. The large
ED01 study, in which the National Center for Toxicological Research
(NCTR) used over 24,000 mice to study the dose-dependence of the car-
cinogenicity of 2-acetylaminofluorene (AAF), gave responses that were
described as nonthreshold for liver carcinogenesis and threshold for
bladder (reviewed in Eaton and Gilbert 2008). The ED01 study was also
controversial with respect to hormesis. A task force of the Society of
Toxicology (SOT) pointed out that lifespan was longer and the incidence
of bladder tumors lower in animals receiving low doses of AAF than in the
controls (Society of Toxicology Task Force 1981; Bruce et al. 1983), a
claim contested by the NCTR (Kodell et al. 1983). The SOT Task Force
(Bruce et al. 1983) concluded credibly that even in such a large study “sta-
tistical uncertainty makes it impossible to establish the true shape of the
dose response curve.” In a later debate about thresholds in ED01 (Waddell
2003), Melvin Andersen and colleagues noted that the existence of
thresholds is unlikely to be fully resolved by empirical modeling of dose-
response data or by experiments using more animals per group but,
rather, will depend on mechanistic evidence for thresholds (Andersen et
al. 2003). This prediction has bearing on low-dose responses more broad-
ly, including an understanding of hormesis.
Apparent hormesis arising as an artifact
Among the difficulties that affect the observation of hormesis is the
existence of artifacts that can falsely give the appearance of hormesis
where it does not exist. If one pools endpoints into a composite (e.g., car-
cinogenesis, pooling tumors at several sites), one may generate hormetic
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curves in the absence of real hormesis; for example, if a modest decline
in the first endpoint at low dose (e.g., tumors at site A) is offset by a larg-
er increase in another endpoint at higher doses (e.g., tumors at site B),
the composite (i.e., tumors in general) can take the form of a hormetic
J-shaped curve (Thayer et al. 2005). In measuring a decline in biological
function owing to toxicity, a control that is atypically low may cause meas-
urements at low doses, even if slightly toxic, to seem hormetic (Thayer et
al. 2005). Likewise, in measuring an adverse effect, a control with an atyp-
ically high spontaneous incidence can create the illusion of hormesis at
low doses. The existence of such possibilities does not argue against the
existence of hormesis in general, but it does emphasize the need for crit-
ical judgment and an awareness of potential artifacts in the assessment of
hormesis.
The distinction between an essential substance and a xenobiotic tox-
icant is usually clear (Davis and Svendsgaard 1990), but there is some
potential for confusion (Kefford et al. 2008). Adverse effects occur when
physiologically essential chemicals are present at doses that are either too
low or too high (Gaylor 1998). Essentiality can mimic hormesis when
nutritional stimulation merges with toxicity (Kefford et al. 2008). If one
measures growth or another indicator of biological function at different
concentrations of an essential chemical, one sees no growth at dose zero,
increases in growth with increasing concentration in a zone of deficiency,
an optimum, and then a decline with the onset of toxicity at high dose.
In natural environments, many substances are present at doses above
zero, so the ordinate is effectively moved to the right, and this can create
a curve resembling a hormetic inverted U. Confusion between essentiali-
ty and hormesis is unlikely if the optimum is broad, because the effects
would appear as two curves in different dosage ranges. In ecological set-
tings, however, essentiality may artifactually resemble hormesis. For
example, if a toxicant or complex mixture contains a mineral nutrient
that stimulates plant growth in the subtoxic zone, the dose-response
curve may not differentiate this stimulatory response from hormesis.
Evaluating the prevalence of hormesis
Hormesis is commonly observed in toxicological literature, but
debate continues about its generality. The existence of many biphasic
curves does not demonstrate the prevalence or universality of hormesis.
Difficulties in using published literature to evaluate the prevalence of
hormesis are that many studies have too few doses in the low-dose range,
and the choice of studies for evaluation may introduce bias.
Disagreement persists on whether hormesis can be described as rare,
occasional, common, highly prevalent, or even universal. The evidence of
the last decade argues that rare or occasional are not apt descriptions, but
the approach to universality is a high hurdle.
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The accumulation of examples of hormesis has led proponents, espe-
cially Edward Calabrese, to argue with growing confidence that the fun-
damental nature of dose-response relationships in toxicology needs to be
reevaluated (Calabrese and Baldwin 1999; Calabrese et al. 1999) and that
hormesis should be the “default” assumption in toxicology (Calabrese
and Baldwin 2003c) and toxicological risk assessment (Calabrese 2004,
2008a). Skeptics challenge the assertion that hormesis is highly prevalent
or universal, do not agree that it is broadly generalizable, and reject the
idea that it can serve as a default assumption (Kitchin and Drane 2005;
Thayer et al. 2005; Mushak 2007). Crump (2001) noted the lack of a sta-
tistical test that specifically evaluates hormesis. While this assertion is
essentially correct, it tends to minimize the value of statistical measures
that have been used to analyze specific extensions of the hormesis
hypothesis, such as whether low-dose responses differ significantly from
the control in the direction consistent with hormesis. Such statistical
measures, however, are not free of controversy; for example, there is dis-
agreement about whether appropriate corrections are made for multiple
comparisons (Kitchin and Drane 2005). Recent analyses of biphasic dose
responses have increasingly taken advantage of statistical modeling tech-
niques (Schöllnberger et al., 2001, 2006; Cedergreen et al., 2005; Cox,
2005; Calabrese et al., 2008; Leonard, 2008).
Crump (2001) has argued that one cannot judge the generality of
hormesis on the basis of there being many examples in the scientific lit-
erature because of the lack of a reliable denominator that serves as a basis
for quantifying the prevalence of hormetic curves. This criticism is justi-
fied when applied to the many papers that point out examples of horme-
sis but do not rigorously evaluate its prevalence relative to other models
in a clearly defined number of studies. Such studies do not consider rates
of false positive responses; and they often do not correct adequately for
possible bias in the selection of studies that seemed hormetic.
Progress in addressing these criticisms was made by Calabrese and
Baldwin (2001a) in a survey of over 20,000 articles in three toxicology
journals. Rigorous a priori entry and evaluative criteria were used, and
studies were chosen for inclusion on the basis of whether they permitted
an evaluation of the low-dose zone, not on whether they seemed to show
hormesis. Of roughly 20,000 articles, only 1% (195/ 20,285) had suffi-
cient experimental designs, and they contained 668 dose-response rela-
tionships that could be evaluated. The majority of studies were excluded
because they did not have appropriate controls, at least two doses below
the NOAEL, or a toxic response at high dose (Calabrese and Baldwin
2001a,b). Most dose-responses that met the entry criteria were inconclu-
sive, but about 37% (245/668) provided evidence of hormesis, as indi-
cated either by statistical significance or by a 10% difference from the
control in ≥3 sub-NOAEL doses (Calabrese and Baldwin 2001b). The
G. R. Hoffmann
16
16
Dose-Response: An International Journal, Vol. 7 [2014], Iss. 1, Art. 2
https://scholarworks.umass.edu/dose_response/vol7/iss1/2
issue of false positives was tackled by evaluating the relative number of
positive and negative responses at sub-NOAEL doses, using the assump-
tion that if random variation caused false positives, their number would
be equal to responses deviating from the control in the opposite direc-
tion. The occurrence of false positives could not explain the excess of
apparently hormetic responses. While 80% of responses below the
NOAEL did not differ significantly from the control, 19.5% differed sig-
nificantly from the control in the direction expected for hormesis, while
0.6% differed from the control in the opposite direction, a 32-fold dif-
ference in support of hormesis (Calabrese and Baldwin 2001a).
Depending on the stringency of the criterion used for declaring a
response nonmonotonic, one might conclude that 19.5 to 37% of the
responses in the large survey of Calabrese and Baldwin (2001a) gave evi-
dence of hormesis. A smaller survey by Davis and Svendsgaard (1994) had
earlier estimated 12 to 24%. In a subsequent analysis by Calabrese and
Baldwin (2003a), predictions of a threshold model were compared with
those of the hormesis model for 1800 published doses below the NOAEL
in 664 dose-responses. The a priori criteria for inclusion were having a
toxic dose, a NOAEL, two doses below the NOAEL, and a concurrent
control. Whereas the threshold model would predict a ratio of approxi-
mately 1:1 for responses above and below the control in the sub-NOAEL
zone, a ratio of 2.5:1 was observed (Calabrese and Baldwin 2003a).
Although it is now clear that hormesis is evident in literature studies
that have a well-defined denominator, it should be kept in mind that
other tabulations of hormetic responses still have an inherent limitation
if the denominator is not defined (Crump 2001, Mushak 2007).
Moreover, there is no agreement on the frequency at which hormesis
must be demonstrable to make a persuasive case that it is a generalizable
phenomenon. Thus, findings that 12-24% (Davis and Svendsgaard 1994)
or 19.5-37% (Calabrese and Baldwin 2001a) of papers that qualify for
evaluation are nonmonotonic have been used both as an argument for
(Calabrese and Baldwin 2001a) and against (Mushak 2007) the preva-
lence of hormesis. Such differences of interpretation call for restraint in
asserting the generalizability of hormesis, but they do not negate the fact
that hormetic responses are widespread.
Hormesis is observed throughout the phylogenetic spectrum, includ-
ing bacteria, fungi, algae, plants, insects, other invertebrates, fish, birds,
and mammals (Calabrese and Baldwin 2001a, 2003a; Calabrese and Blain
2005). It encompasses diverse biological endpoints, including those that
have been categorized as metabolic, growth, reproductive, molecular,
behavioral, physiological, or survival (Calabrese and Baldwin 2001a,
2003a). The diversity includes radiation and varied organic and inorgan-
ic chemicals and mixtures (Calabrese and Baldwin 2001a, 2001b, 2003d,
2003e, 2003f; Calabrese and Blain 2005). No broad category of organism,
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endpoint, or agent consistently fails to give evidence of hormesis. Such
diversity suggests that the phenomenon of hormesis is generalizable
beyond the many specific examples (Calabrese 2008a).
Paucity of experiments designed to evaluate whether responses are
hormetic
Despite the interest that hormesis has generated, there are relatively
few experiments specifically designed to evaluate whether responses are
hormetic. Therefore, the occurrence of hormesis is often identified in
studies conducted for reasons other than measuring hormesis. As a con-
sequence, there is a shortage of data on the reproducibility of hormetic
responses (Kitchin and Drane 2005). More attention to low doses is a
pressing need (Calabrese and Baldwin 2002a; Calabrese 2008a), both for
evaluating the nature of hormesis and for evaluating the hypotheses of
those who claim that adverse effects of low-doses may sometimes be
greater than expected under linear or threshold models. The latter
include the possibility that endocrine disruptors have adverse effects at
doses that would otherwise be considered nontoxic (vom Saal and
Sheehan 1998; Timms et al. 2005; Welshons et al. 2003; vom Saal and
Hughes 2005). The ability to detect hormesis is favored by there being sev-
eral closely-spaced doses immediately below the NOAEL (Calabrese
2008a), such as half-log or twofold increments, and enough statistical
power to resolve small changes. Many toxicological studies do not fulfill
these requirements, and even if they do, the observation of hormesis may
depend on temporal components in the relationship of exposure to
response that were not included in the study design, such as time required
for induction of an adaptive response (Calabrese and Baldwin 2001b).
While it is true that there are relatively few studies specifically
designed to measure hormesis, it is not true that experiments clearly
showing hormesis are lacking. What is needed is an assay with appropri-
ate background levels of response and the sensitivity to measure small
changes. Unequivocal evidence of hormesis has been obtained by
Redpath and colleagues using an in-vitro assay for neoplastic transforma-
tion in the HeLa x human skin fibroblast hybrid cell line CGL1. X rays of
an energy widely used in diagnostic radiology (60 kVp) caused hormesis,
indicated by transformation frequencies less than the spontaneous fre-
quency at doses <10 cGy (Redpath et al. 2003a). The maximum hormet-
ic effect was at 0.1 cGy (Redpath et al. 2003a; Redpath 2006). The obser-
vation of hormesis depended on a delayed plating scheme, whereby cells
were seeded after 24h of post-irradiation holding (Redpath et al. 2003a).
The time requirement for expression of the hormetic effect is parallel to
the importance of time for the expression of adaptive responses in con-
ditioning hormesis.
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Hormesis was also observed after exposure of CGL1 cells to low doses
(≤10 cGy) of 137Cs γ rays (Redpath et al. 2003a; Redpath 2006). While not
exactly parallel, the two studies provide a preliminary comparison of the
two treatments (Redpath et al. 2003a). The higher-LET 50 kVp x rays had
a lower threshold for damage and caused greater damage at high doses
than the more energetic γ rays. However, their relative biological effective-
ness (RBE) appeared to be higher not only for inducing damage at high
dose but for protecting against damage at low dose (Redpath et al. 2003a).
Both the X- and γ-ray assays clearly show hormesis. While hormesis is usu-
ally observed at doses <5-10 cGy (Redpath et al. 2003a; Redpath and
Elmore 2007), very low dose rates of low-LET radiation (~ 0.5 mGy/min)
produced hormetic effects at higher doses, and no transformation was
induced even at doses as high as 1 Gy (Elmore et al. 2006; Redpath and
Elmore 2007). Mechanisms of radiation hormesis in the HeLa x fibroblast
transformation assay apparently involve the induction of DNA repair and
the selective death of a subpopulation of cells prone to spontaneous trans-
formation at low doses (Redpath et al. 2003a, 2003b; Redpath 2006).
Another exquisitely sensitive assay has permitted the detection of
hormetic effects for a genetic endpoint in mice in vivo. Sykes and col-
leagues have developed assays for the detection of chromosomal inver-
sions that arise by somatic intrachromosomal recombination (SICR). The
SICR assays are based on a genetic construct that permits the detection
of inversions in various tissues of pKZ1 transgenic mice or in pKZ1 cell
cultures in vitro (Sykes et al. 2006). The transgene has the E. coli lacZ gene
in reverse orientation with respect to a chicken β-actin promoter. It is
flanked by mouse immunoglobulin gene recombination signal sequences
J
κ5 and Vκ21C. When an inversion occurs in the transgene, the lacZ gene is
brought into correct association with the β-actin promoter, and expres-
sion of the lacZ gene can be detected by a blue staining reaction (Sykes et
al. 2006). Inversions in the pKZ1 assay probably arise through the activity
of proteins involved in repair of DNA double-strand breaks by nonho-
mologous end joining (Sykes et al. 2006). The pKZ1 assay is especially
sensitive to low doses of DNA-damaging agents in lymphoid tissue (Sykes
et al. 2006). Genetic effects are detected at doses over 1000-fold lower
than those detected in other mouse assays (Hooker et al. 2002; Sykes and
Day 2007). High spontaneous frequencies of inversions in the pKZ1 assay
(~1.6 x 10-4 in spleen) make it practical to measure decreases in inversion
frequency, which occur with hormesis, as well as the increases induced by
genetic damage at high doses (Hooker et al. 2002; Sykes et al. 2006; Sykes
and Day 2007).
Etoposide, a DNA topoisomerase II inhibitor that interferes with
DNA and RNA synthesis and is genotoxic in various assays, is an effective
inducer of SICR in the pKZ1 assay (Hooker et al. 2002). Doses of 0.05 to
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50 mg/kg in a single intraperitoneal injection increased SICR inversions
1.4- to 3.1-fold. However, inversion frequencies after treatment with
0.0005 and 0.005 mg/kg were decreased significantly to 0.67 and 0.43 of
the control levels (Hooker et al. 2002). Thus, there was a hormetic effect.
Hormesis is also detected in pKZ1 cells in vitro. A pKZ1 mouse hybrido-
ma cell line exposed to etoposide showed 2.3- and 4.6-fold increases in
inversion frequencies at 100 and 1000 nM, respectively. However, there
was hormesis at low doses, with inversion frequencies decreased to 0.31
and 0.5 of control levels at 1 and 10 nM, respectively (Hooker et al. 2002).
Understanding of mechanisms
A criticism that has been raised about the hormesis concept is that
there is insufficient understanding of mechanisms to form a coherent view
of hormesis within the broader context of biology (Stebbing 2003; Kitchin
and Drane 2005; Thayer et al. 2005). It is true that establishing the mech-
anistic foundations of hormesis is critical. On the other hand, hormesis is
well-documented at the phenomenological level, and it increasingly
appears to be a manifestation of a broad family of stress responses
(Calabrese et al. 2007), including adaptive responses and precondition-
ing. Some of these responses are reasonably understood at a mechanistic
level. While hormesis is still primarily defined on the basis of dose-
response relationships, there is a growing appreciation for mechanisms
that can explain hormetic effects. The evidence suggests that there is no
single mechanism of hormesis but, rather, many mechanisms that yield the
common features of the hormetic dose response (Calabrese 2008a). Table
2 gives examples of mechanisms that can explain hormetic effects. 
One might expect the first interaction between a toxicant and its tar-
get to follow the law of mass action and exhibit a monotonic response.
However, in a complex biological system various mechanisms can lead to
nonlinearity. Deviations from linearity are favored by the occurrence of
multiple concurrent and sequential events in toxicologic responses. In
some instances, a biphasic response can be understood as the superim-
position of monotonic responses of the system’s components on one
another (Conolly and Lutz 2004). In other cases, biphasic curves are like-
ly to result from complex interactions of an exogenous agent with a uni-
tary biological system (Conolly and Lutz 2004; Fukushima et al. 2005).
Mechanisms that can contribute to hormesis are found in literature on
the hormesis concept itself (Calabrese and Baldwin 2001c; Calabrese
2002), quantitative aspects of dose-response curves (Conolly and Lutz
2004; Fukushima et al. 2005) and stress responses (Mattson et al. 2004;
Miura 2004; Arumugam et al. 2006; Calabrese et al. 2007).
A combination of experimental evidence and credible speculation
suggests that hormesis occurs when a system overcompensates for a dis-
ruption in homeostasis, effectively overshooting homeostatic feedback
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controls (Calabrese 2002; Conolly and Lutz 2004) and that the modest
overcompensation reestablishes homeodynamic balance (Rattan 2008).
Hormetic mechanisms for coping with oxidative stress are apt to involve
enhanced antioxidant defenses, including the generation of endogenous
scavengers, quenching agents, and enzymes of detoxication (Benzie
2000; Miura 2004; Arumugam et al. 2006; Chen et al. 2006b). Hormesis
and adaptive responses can arise from the activation of transcription fac-
tors and upregulation of genes encoding cytoprotective proteins (e.g.,
heat-shock proteins), growth factors, cytokines, and enzymes involved in
various signaling pathways (Stecca and Gerber 1998; Mattson et al. 2004;
Miura 2004; Arumugam et al. 2006). Interactions of exogenous sub-
stances with stimulatory and inhibitory receptor subtypes of endogenous
regulatory systems have been identified as mechanisms underlying some
hormetic responses (Calabrese and Baldwin 2001c; Calabrese 2002,
2008a; Conolly and Lutz 2004; Joëls 2006), as have enhanced immune
responses (Conolly and Lutz 2004). Differences in minimal doses
required to trigger protective and detrimental effects involving interac-
tions among cell proliferation, cell-cycle delay, apoptosis, and DNA dam-
age (Rouse and Jackson 2002; Conolly and Lutz 2004; Fukushima et al.
2005; Kinoshita et al. 2006) could lead to hormesis in several ways.
Selective induction of apoptosis by low levels of oxidative damage or radi-
ation in transformed cells compared to normal cells (Heigold et al. 2002;
Bauer 2007; Portess et al. 2007) and death of cells predisposed to spon-
taneous transformation (Redpath et al. 2003a; Redpath 2006) fit this gen-
eral pattern. Preferential induction of adaptive responses in normal cells
relative to cancer cells may similarly contribute to hormetic responses
(Ishii and Watanabe 1996; Park et al. 1999).
Some adaptive responses, also called conditioning hormesis
(Calabrese et al. 2007), have been ascribed to the induction of repair
processes that remove damage caused by the inducer (Shevell et al. 1990;
Perspective on hormesis
21
TABLE 2. Mechanisms Contributing to Hormetic Responses at Low Doses
Overcompensation to a disruption in homeostasis by overshooting homeostatic feedback controls.
Adaptive responses based on inducible repair processes.
Enhanced defenses against oxidative stress.
Activation of transcription factors and upregulation of genes for cytoprotective proteins, growth
factors, cytokines, and enzymes involved in various signaling pathways.
Interaction of exogenous agents with stimulatory and inhibitory receptor subtypes of endogenous
regulatory systems.
Interactions among cell proliferation, cell-cycle delay, apoptosis, and DNA damage.
Selective induction of apoptosis in transformed cells and death of cells predisposed to spontaneous
transformation.
Preferential induction of adaptive responses in normal cells relative to cancer cells.
Enhancement of gap junction intercellular communication at low doses but inhibition at high
doses.
Enhanced immune responses.
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Wolff 1998; Kleibl 2002; Miura 2004). If the repair mechanism also
removes damage caused by background levels of exposure or endoge-
nous agents, it can yield a biphasic hormetic curve (Kodell 2001; Conolly
and Lutz 2004). Alteration of cell cycle regulation after a conditioning
dose is another mechanism favoring an adaptive response through more
effective DNA repair (Miura 2004). Gap-junction intercellular communi-
cation (GJIC) is implicated in hormetic mechanisms, in that its disrup-
tion can block an adaptive response to ionizing radiation (Ishii and
Watanabe 1996). Enhancement of GJIC at low doses, combined with its
inhibition and loss of function at high doses, is a mechanism associated
with hormesis for nongenotoxic carcinogens (Fukushima et al. 2005) and
physiological preconditioning (Lin et al. 2008). A possible mechanistic
basis for U-shaped curves with endocrine disruptors is that high doses
may trigger a reduction in the number of hormone receptors in hor-
mone-responsive cells, while lower doses lead to an increase in receptors
(vom Saal and Sheehan 1998).
POLITICAL AND ETHICAL ISSUES CAUSING CONTROVERSY ABOUT
HORMESIS
The intensity of the debate about hormesis is often centered on its
societal implications rather than on the science itself. There is much
argument about whether hormesis should enter into policy related to
effects of low-dose exposures. Emotions run high owing to fear that the
recognition of hormetic effects can undermine protections of human
health and environmental quality. The hormesis concept suggests that
low doses may be beneficial, but defining what is actually beneficial, con-
sidering both short-term and long-term consequences, is complex. It can
be a serious error to conclude overall benefit on the basis of a single bio-
logical endpoint at a particular point in time. Thorough analysis is criti-
cal to avoid a premature claim of hormesis. Ignoring benefit, a hormetic
model also suggests that low doses pose less risk than predicted by an
LNT model. While this may be seen as good news, it can also be seen as
an argument for weaker protective standards. Thus, the intensity of the
debate is fueled by concerns about the ethical, social, and legal implica-
tions of hormesis. Disagreements about hormesis are often exacerbated
by a tendency to conflate science and policy, blending what are funda-
mentally scientific questions with what are essentially social or political
questions. Separating the two cleanly may be nearly impossible owing to
the social factors and value judgments that enter into scientific practice.
Nevertheless, failing to maintain an awareness of the boundaries can hin-
der both scientific understanding and the path to sound policies
(Hoffmann and Stempsey 2008).
The unique attributes of biphasic responses are central to the con-
troversy. A threshold model (Figure 1A) holds that there is a dose,
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approximated by a NOAEL, below which there is no net biological effect,
either positive or negative. Under an LNT model (Figure 1B), all doses
are considered to have an adverse effect. Thresholds and LNT are inher-
ently simpler than hormesis for risk assessment because they lend them-
selves to the sole objective of avoiding harm. Under a threshold model,
one seeks to be in the no-effect zone, and a safety factor may be imposed
below the NOAEL to ensure the avoidance of harm. In the case of LNT,
the objective is to be low enough on the dosage scale that the risk is neg-
ligible or acceptable. Hormesis raises the question of whether one should
strive to be far enough below the zone of biological activity to ensure
avoidance of harm or whether to permit or even encourage low-dose
exposures that may be beneficial. The questions escalate in complexity
when one contemplates the relationship of biphasic curves to hetero-
geneity among endpoints and agents, sensitive subgroups in populations,
interactions among agents, and the political and ethical questions raised
by these issues (Hoffmann and Stempsey 2008).
FACTORS SHAPING VIEWPOINTS ON HORMESIS AND RISK ASSESSMENT
It is not surprising that hormesis has been an unwelcome intruder in
toxicological risk assessment, given that biphasic curves pose new chal-
lenges (Hoffmann and Stempsey 2008), and most views of dose-response
relationships have been shaped by linear and threshold models. Factors
that affect viewpoints on hormesis in relation to risk assessment include
divergent perceptions of benefit and risk associated with a hormetic
response, the practicality of assimilating hormesis into the estimation of
hazards, beliefs about whether policy decisions should be based on the
best available science, and ethical principles.
Even if there is agreement that a response is hormetic, that knowl-
edge may trigger different perceptions of risk and benefit. Table 3 pres-
ents divergent views in order of decreasing optimism about benefit and
increasing perception of hazard. All these views can be found among sci-
entists receptive to the hormesis concept. The difficult challenges that
one would encounter in practical applications undoubtedly shape the
broad range of views found among those who are persuaded of the reali-
ty and common occurrence of hormesis.
If we allow threshold and linear models to dominate our thinking
about low doses, we are at risk of basing policies on incorrect models in
the face of growing evidence for hormesis. At the same time, the policies
themselves may be in the public interest, in that the errors tend to over-
estimate risk rather than underestimate it. There is a longstanding pref-
erence for excessive caution, rather than too little caution, in policy deci-
sions, which is the foundation on which the assimilation of a precaution-
ary principle into regulatory decisions is based. On the grounds of uncer-
tainty, one might make a deliberate policy decision not to apply hormesis
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to risk assessment (Hoffmann and Stempsey 2008). If so, one should do
so without conflating science and policy to the extent of arguing against
the existence of hormesis. Risk assessment should be undertaken with
cognizance of the best available scientific evidence. Denying the exis-
tence or common occurrence of hormesis in the face of growing evi-
dence does not protect public health or the environment, but thoughtful
policy decisions made with cognizance of hormesis can. 
RELATIONSHIPS TO ETHICAL PRINCIPLES
Biomedical ethics has traditionally recognized four clusters of ethical
principles: respect for autonomy, beneficence, nonmaleficence, and jus-
tice (Beauchamp and Childress 2001). While autonomy and justice have
had growing recent emphasis, nonmaleficence and beneficence have
historically formed the core of medical ethics. Nonmaleficence entails
avoiding the causation of harm, while beneficence entails the conferral
of benefit, typically in balance with risks and costs (Beauchamp and
Childress 2001).
The bioethical principles of nonmaleficence and beneficence are ger-
mane to the prospect of assimilating hormesis into regulatory policies
(Hoffmann and Stempsey 2008). Most policies related to toxicology are
based on nonmaleficence—avoidance of harm. As an ethical principle,
nonmaleficence has its roots in the medical maxim “above all, do no
harm.” Although the first book of the Epidemics of Hippocrates actually
advised that physicians both avoid harm and do good, ethical theory typ-
ically gives a higher priority to nonmaleficence (Ross 1988; Beauchamp
and Childress 2001). 
The biphasic curve of hormesis (Figure 1C), unlike threshold and lin-
ear responses, holds the prospect not only of avoiding harm in the toxic
zone but of accruing benefit in the hormetic zone. If we assume that the
hormetic zone for a substance can be precisely defined without risk of
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TABLE 3. Divergent Perceptions of Benefit and Risk Associated with a Hormetic Response
In order of perceived risk:
1. Hormesis is good news and should be assimilated into risk assessment:
• Public health would benefit if it becomes possible to regulate to the hormetic zone.
• Hormesis offers the prospect of positively affecting public health, not only avoiding harm.
2. Low-dose risks are probably smaller than anticipated, but application to policy is premature.
3. It is dangerous to try to harvest a hormetic benefit:
• Error in identification of the hormetic zone could lead to exposures in the toxic zone.
• Hormesis is a relatively modest effect, whereas toxic effects can be great.
• Prudence argues for steering further from the brink of toxicity.
4. Hormesis suggests proximity to the toxic zone and should be taken as a warning:
• Benefits in one biological response may be offset by detriment in others.
• Some superficially beneficial effects may cause long-term harm.
• Some individuals may experience hormesis while others experience toxicity.
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inadvertently entering the toxic zone, policies could, in principle, be for-
mulated so as to allow optimum exposures rather than maximum per-
missible exposures. Attempting to harvest the benefit of the hormetic
zone would entail a shift in ethical principle to beneficence, displacing
the nonmaleficence that characterizes most current policies on toxicants
(Hoffmann and Stempsey 2008). There is precedent for public-health
policy based on beneficence, such as fluoridation of water supplies and
mandated vaccination programs. Such measures often entail controversy,
but the public largely accepts them if the evidence is clear. Cook and
Calabrese (2006) have argued that hormesis opens the possibility of
improving public health, rather than striving to maintain disease and dis-
ability near background levels, thus promoting public health rather than
only protecting it. Such a change from nonmaleficence to beneficence
would have to resolve whether it is possible to define benefit precisely to
optimize health without incurring an unacceptable risk of harm. In con-
sidering hormesis in a policy setting, it is necessary to balance nonmalef-
icence and beneficence with a higher priority given to the former.
HORMESIS AND THE ESTIMATION OF HAZARDS
Regulating for hormesis would pose formidable information
demands. One must know that the hormetic zone can be precisely tar-
geted without risking harm. Accruing a hormetic benefit implies regulat-
ing to a level closer to the ZEP or NOAEL than is currently done.
Asymmetry around the NOAEL is an inherent problem, in that hormetic
effects tend to be modest, whereas toxic effects can be large. The require-
ment for greater precision in identifying points of transition in dose-
response relationships is a formidable challenge because of the difficulty
of measuring effects at low doses.
Precise knowledge of a chemical’s effect for a given endpoint or geno-
type does not provide a basis for extrapolation to other situations. For
example, the same doses of cadmium chloride that appear to show
hormetic effects for testicular tumors (Waalkes et al. 1988; Calabrese and
Baldwin 1998; Calabrese and Baldwin 2003d) induce prostate tumors
(Waalkes et al. 1988; Thayer et al. 2006). Testicular carcinogenesis is
apparently impeded at low doses because it depends on testicular degen-
eration (Waalkes et al. 1988), and prostate carcinogenesis is impeded at
higher doses where testicular toxicity interferes with the testosterone pro-
duction on which it depends (Goyer et al. 2004). To avoid concluding
safety or benefit on the basis of inappropriate or insensitive indicators,
one must know that a presumptive benefit is not offset by adverse effects
elsewhere (Davis and Svendsgaard 1990; Davis and Farland 1998; Mushak
2007), and it may not be obvious which endpoints are most sensitive for
a given exposure. Those who think that hormesis is ready for use in risk
assessment for chemicals, including chemical carcinogens, might consid-
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er accepting the challenge of Paul Mushak, a critic of hormesis who has
argued that proponents “have not yet laid out a convincing methodolog-
ic schematic that actually walks the reader or risk assessor through a
hormesis-based quantitative risk assessment” (Mushak 2007).
There is little disagreement that underestimation of hazards can lead
to insufficient protection of public health and the environment. In con-
trast, overestimation of risk is often considered benign, as reflected in the
phrase “making errors on the side of safety.” However, there is room for
disagreement on this point, as an overestimation of risks can have such
costs as greater regulatory burden than needed and hindrance of the
development and use of improved products and technology.
LNT has received support in radiation risk assessment even after
mechanisms that can cause departures from linearity were known
because it would tend to overestimate risk rather than underestimate it.
This was stated directly in the 1980 report of the NAS Committee on the
Biological Effects of Ionizing Radiation (National Research Council
1980), which recommended the use of LNT for “reasons of prudent con-
servatism,” but acknowledged that the available data did not permit a rig-
orous evaluation of what actually happens at low doses. The latest NAS
report continues its support of LNT (National Research Council 2006).
Arguments for LNT can be advanced on its merits as a conservative
approach and a simple tool in risk assessment or on its merits as a model
that describes actual dose-response relationships (Breckow 2006; Friedl
and Rühm 2006). While there is disagreement on both counts, a coher-
ent argument can be made for the former more readily than the latter,
and the boundary between scientific interpretation and policy judgment
should not be blurred.
Many would agree that the avoidance of health risks should be
weighed more heavily than economic interests. However, the view that
overestimating risk may lead to expenditures for minimizing exposures
but cannot threaten public health is questionable. The Joint Report of
the French Academies (Aurengo et al. 2005; Tubiana and Aurengo 2006)
warned that there can be health risks associated with an exaggeration of
hazards of low doses of ionizing radiation if it leads to an avoidance of
beneficial diagnostic procedures or therapy. More pointedly, Scott and Di
Palma (2006) have argued that trust in LNT has led to fear of diagnostic
procedures that use doses for which hormesis is likely (e.g., dental x rays,
chest x rays, mammograms, thyroid scans). Although there is disagree-
ment on the likelihood that fear of radiation exposure will lead to unwise
avoidance of diagnostic or therapeutic procedures (Scott and Di Palma
2006; Tubiana and Aurengo 2006; Hall and Brenner 2008), a balanced
perspective should recognize that there can be detrimental effects both
of underestimating and of overestimating risks.
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POSSIBLE CONSEQUENCES OF IGNORING OR REJECTING HORMESIS
Ignoring or rejecting hormesis can be detrimental to science and
public health. A better understanding of hormetic effects can yield ben-
efits in various areas of the biomedical and environmental sciences.
Effects on low-dose research
Recognition of hormesis calls for more research on effects of low
doses and biological stress responses. There is less incentive for research
on these subjects if one believes that everything of interest occurs in the
high-dose range and that effects at low doses are predictable from those
at high doses. A failure to recognize the unique biological responses that
occur in the low-dose zone can stifle progress in diverse areas of public
health, medicine, agriculture, and environmental sciences.
Biological stress responses and health optimization
Stress responses are important to muscular, skeletal, cardiovascular,
and neurological health (Arumugam et al. 2006; Radak et al. 2008). It has
been suggested on this basis that biological systems must routinely expe-
rience mild stress for optimization of health (Calabrese 2008a) and that
hormetins—agents that induce hormesis—can contribute to healthy
aging, which is favored by mild and periodic physical and mental chal-
lenges but disfavored by severe or chronic stress (Rattan 2008). Even
though the effectiveness of stress responses tends to decline with age
(Miura 2004; Rattan 2008), such factors as exercise, cognitive stimulation,
and calorie restriction may improve health, extend lifespan, and lessen
the risk of such age-related disorders as Alzheimer’s disease, Parkinson’s
disease, and stroke through what have been called “hormesis-like mecha-
nisms” (Mattson et al. 2004; Arumugam et al. 2006).
The beneficial effects of exercise can be considered as the hormetic
zone of a biphasic curve, with adverse effects on one side caused by inac-
tivity and on the other by excessive exercise and overtraining (Radak et al.
2008). The generation of reactive oxygen species apparently plays a central
role in causing modest levels of oxidative damage to macromolecules, trig-
gering stress responses that combat oxidative stress (Radak et al. 2008).
Common features of neurodegenerative disorders that make them subject
to beneficial effects of conditioning are increased oxidative stress, impaired
energy metabolism, and disruption of cellular calcium homeostasis
(Mattson et al. 2004). Biphasic dose responses are reported in diverse areas
of neurosciences, including neuroprotection, neurite outgrowth, and
responses to drugs for Alzheimer’s disease, Parkinson’s disease, anxiety,
pain, seizures, and stroke (Calabrese 2008b, 2008c). Accumulating evi-
dence in support of a “hormesis hypothesis of disease resistance and
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longevity” (Arumugam et al. 2006) gives impetus to achieving a fuller
understanding of biological stress responses, which can lead to practical
dietary, behavioral, and therapeutic methods (Mattson et al. 2004).
Agricultural and environmental aspects of hormesis
A failure to recognize and understand hormesis can have adverse
effects not only in the biomedical sciences but also in agricultural and
environmental sciences. For example, the hormetic stimulation of pests
peripheral to those targeted with high doses of pesticides may be a factor
in secondary pest outbreaks (Morse 1998). Hormetic effects in insects,
often called hormoligosis rather than hormesis, have been observed after
exposure to various pesticides (Luckey 1968; Morse and Zareh 1991;
Fujiwara et al. 2002). Citrus thrips, which are a major pest of California
citrus, exhibit a hormetic response when fed on lemon leaves containing
low doses of organochlorine (dicofol), organophosphate (malathion),
carbamate (formetanate) and pyrethroid (fluvalinate) insecticides
(Morse and Zareh 1991). Doses expected to cause 1-25% mortality of
adult females reduced fecundity, but doses predicted to cause 0.01 - 1%
mortality led to an increase in fecundity (Morse and Zareh 1991). It is
widely recognized that the formulation of pest-control strategies requires
an understanding of toxic effects in pests, including insects, mites, and
nematodes, as well as in host species and other nontarget organisms.
Although less widely recognized, it is also important to understand
hormetic effects in pests and in their natural predators and competitors
(Morse 1998; Kefford et al. 2008).
Understanding the agricultural and ecological implications of horme-
sis requires consideration of hormetic processes in plants. Plants are well-
represented in the hormesis literature (Calabrese and Baldwin 2001a,
2003a; Belz et al. 2005; Calabrese and Blain 2005; Duke et al 2006;
Cedergreen et al. 2007; Velini et al. 2008). Endpoints for which hormesis
has been observed include growth of stems, roots, and leaves; dry weight;
height; protein content; and resistance to pathogenic fungi. Progress has
been made in describing and quantifying plant hormetic responses by
nonlinear mathematical modeling (Belz et al. 2005; Cedergreen et al.
2005). Many herbicides are among the agents shown to induce hormesis
in plants (Duke et al. 2006). Allelopathic compounds, which are general-
ly known as plant metabolites that are inhibitory to other plants, are also
hormetic, in that stimulatory responses are evoked by low doses of such
compounds as parthenin or benzoxazolin-2(3H)-one (Belz et al. 2005;
Duke et al. 2006), and allelopathic plants at low densities can stimulate
rather than inhibit neighboring plants (Belz et al. 2005). Cedergreen et
al. (2007) analyzed 687 dose-response curves for effects of 9 herbicides, a
fungicide, and binary mixtures of the compounds on an alga
(Pseudokirchneriella subcapitata) and three vascular plants (Lemna minor,
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Tripleurospermum inodorum, and Stellaria media). Hormetic responses were
recorded in all species. They were most evident with the herbicides
glyphosate and metsulfuron-methyl but were also observed with the other
compounds. Possible artifacts that could lead to erroneous claims of
hormesis were considered, and hormesis was observed independently of
altered interspecific competition (Cedergreen et al. 2007), which can be
an important factor in natural populations (Duke et al. 2006; Cedergreen
et al. 2007).
Effects of glyphosate have been studied in greenhouse experiments
with maize, soybean, Eucalyptus grandis, Pinus caribea, and Commelia beng-
halensis, all of which showed hormesis at low doses and toxicity at high
doses (Velini et al. 2008). Hormesis was measured as increases in dry
weight of different plant organs, and it was also observable by growth dif-
ferences in Eucalyptus. Glyphosate-resistant soybeans did not show the
hormetic effect. Hormesis can have unforeseen consequences if it occurs
by herbicide drift at sites removed from the target. It may also be exploit-
ed agriculturally, and this may already be occurring in the widespread use
of low doses of glyphosate to enhance sucrose accumulation in sugarcane
(Dusky et al. 1986; Su et al. 1992; Duke et al. 2006; Velini et al. 2008). 
Hormetic effects may be beneficial to the exposed organism if they
confer such attributes as improved pathogen resistance, but their net
effect would be less clear if different low-dose effects offset one another.
For example, increased numbers of offspring may be counterbalanced by
lower offspring survival (Duke et al. 2006). Such trade-offs are suggested
by the observation that diamondback moths treated with the pyrethroid
insecticide fenvalerate at moderately toxic dosages (e.g., LD12.5 -LD25) laid
more eggs than untreated moths, but the eggs tended to be smaller and
exhibited lower viability (Fujiwara et al. 2002). Thus, there may be a
broader partitioning of resources among eggs rather than a net increase
in resource allocation to reproduction. In studies of blowfly development,
Nascarella et al. (2003) found that larvae exhibited hormesis when
exposed to cadmium in their feed. Low doses led to enhanced pupation,
whereas higher doses were toxic and reduced pupation. However, the
hormetic effect at low doses was offset by stage specific toxicity later in
development, manifesting itself as reduced emergence of adults from the
pupae (Nascarella et al. 2003). Conflicting effects of toxicants on survival
and reproduction and differences among life-history stages suggest that
population growth rate may be a better measure of toxicant effects in eco-
logical settings than are effects at the individual level (Forbes and Calow
1999). Such studies raise an evolutionary question going beyond short-
term ecological or agricultural effects and requiring further analysis:
How do hormetic responses for specific biological characteristics in a
given species relate to general fitness (Forbes and Calow 1999; Forbes
2000; Nascarella et al. 2003; Duke et al. 2006; Kefford et al. 2008)?
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Two faces of hormesis in public health and medicine
In public health and medicine, the risks of ignoring hormesis can fall
on two sides—failure to recognize it when biological effects in the
hormetic zone are harmful, and failure to derive hormetic benefit from
low-level stressors. It may be easier to achieve agreement on the former.
If patients suffer adverse effects when low drug doses cause hormesis in
pathogens or parasites, few would argue against modifying therapeutic
regimens so as to take corrective action. Such actions would be rooted in
the principle of nonmaleficence. The likelihood of identifying such risks
is greater if there is general awareness that hormesis is an expected con-
sequence of low-dose exposures. Such cases are more likely to be over-
looked if there is a lack of awareness of the nature of hormesis or resist-
ance to it on the basis of tradition or fear of its implications.
Some current medical practices, rooted in nonmaleficence, may have
beneficial effects through hormesis, although they are not generally rec-
ognized as such. Scott and Di Palma (2006) have described several means
by which hormesis induced by low-dose ionizing radiation can have anti-
cancer effects. The concept of medical radiation hormesis holds that
diagnostic x rays and nuclear medicine prevent cancer not only through
the benefits of diagnosis but biologically. In contrast, therapeutic radia-
tion hormesis encompasses the curative capacity of low-dose fractionated
exposures or low-dose, low-dose-rate therapy for pre-existing cancer,
either alone or in combination with apoptosis-sensitizing chemicals. They
also consider environmental radiation hormesis whereby exposure to
background ionizing radiation may protect against cancer and other dis-
eases (Scott and Di Palma 2006).
Encouraging exposures specifically to harvest the benefit of hormesis
would be rooted in beneficence, and this poses a higher hurdle for
acceptance. Even if one is convinced that hormesis should be expected at
low doses and might serve as a default assumption for the scientific inter-
pretation of effects at low doses (Calabrese et al. 2006), one need not
agree that public policy should attempt to regulate to the hormetic zone.
However, caution about changing exposure standards should not entail
adherence to incorrect dose-response models as though they are true
(Hoffmann and Stempsey 2008).
Excessive emphasis on benefit as a corollary of the hormesis concept
may hinder the recognition of hazards when the hormetic zone works
counter to human well-being. Bacterial infections in cystic fibrosis (CF)
are a serious health problem that can be worsened by hormetic stimula-
tion of bacteria (Linares et al. 2006). Pseudomonas aeruginosa is an oppor-
tunistic pathogen of people with CF and other hospitalized patients. It
colonizes the bronchial tree of CF patients, and the recurrent infections
cause lung deterioration and can lead to death. Different classes of antibi-
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otics, represented by tobramycin, tetracycline, and ciprofloxacin, all stim-
ulate bacteria at low doses. By means of a P. aeruginosa microarray, ana-
lyzing 555 genes relevant to colonization, infection, antibiotic resistance,
transcriptional regulation, and stress response, it has been shown that
subinhibitory concentrations of antibiotics can increase the expression of
bacterial virulence determinants (Linares et al. 2006). The case of
Pseudomonas and CF is but one instance of what is probably a common
phenomenon of hormetic stimulation of pathogens by low drug doses.
Davies et al. (2006) have asserted that “All antibiotics, regardless of their
receptors and mode of action, exhibit the phenomenon of hormesis and
provoke considerable transcription activation at low concentrations.”
The same reasoning suggests the possibility of hormetic stimulation
of surviving tumor cells in some chemotherapy regimens (Calabrese
2005a). Clinical evidence that hormesis in hormone-related cancer ther-
apy may sometimes cause stimulation of a tumor, such as “tamoxifen
flare” in metastatic breast cancer, argues that an understanding of bipha-
sic curves is relevant to achieving the desired inhibitory response
(Brandes 2005). Failure to recognize hormesis can be an impediment to
the development of medical remedies that exploit natural adaptive
responses when they are beneficial or combat them when detrimental.
HETEROGENEITY IN SUSCEPTIBILITY TO TOXICANTS
Heterogeneity in susceptibility to toxicants exists at several levels,
including differences among biological endpoints, tissues and organs,
individuals, and species. A hormetic effect for one endpoint may be of
dubious benefit if accompanied by detriment with respect to another
endpoint. For example, a substantially increased risk of carcinogenesis
would outweigh a modest benefit in another category of effect. It would
be acceptable, however, if an important benefit is bought at the cost of
mild detriment elsewhere, as in many drug side effects. One also needs to
know how an exposure that is beneficial at one site affects other tissues or
organs, such as the occurrence of carcinogenesis at one site and anticar-
cinogenesis at another (Haseman and Johnson 1996; Thayer et al. 2005). 
It has been argued that the failure to consider heterogeneity among
individuals in susceptibility to toxicants is a serious weakness of the
hormesis model with respect to risk assessment (Axelrod et al. 2004). In
fact, the problem of accommodating population heterogeneity is not
unique to hormesis but applies to all models. It would nevertheless be
valuable to know whether hormetic responses occur in sensitive subpop-
ulations and whether they are comparable to those in the typical popula-
tion. Comparisons of hormetic curves in published literature have led to
the suggestion that individuals and species exhibiting greater sensitivity
to toxicants usually exhibit hormetic responses, but they occur at lower
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doses (Calabrese and Baldwin 2002b; Calabrese 2008a). While difficult to
evaluate rigorously, a shift of the dose-response curve to the left seems a
reasonable expectation for sensitive groups.
Mitchel et al. (2003) have shown that a radiation-sensitive, cancer-
prone strain of mice (B6.129S2-Trp53tm1Tyj/+) given a single low dose (10
mGy) of 60Co γ rays at a low dose rate (0.5 mGy/min) showed a longer
latency period for the development of spontaneous lymphomas and
spinal osteosarcomas. Preexposure to 10 mGy also made this strain less
susceptible to adverse effects of a large acute dose (4 Gy) of γ rays
(Mitchel et al. 2004). In an NCI yeast database, 11 strains with altered
DNA repair or cell-cycle progression all displayed hormesis (Calabrese et
al. 2006). Such findings support the view that stress responses and horme-
sis occur in sensitive genotypes, but they do not preclude the possibility
that some genotypes will prove to be refractory. 
There is clear evidence of genetic and physiological alterations that
interfere with stress responses. For example, E. coli ada mutants that are
deficient in a methyltransferase that repairs O6-methylguanine in DNA do
not exhibit the adaptive response to methylating agents (Volkert 1988;
Shevell et al. 1990; Kleibl 2002). Similarly, inhibition of poly(ADP-
ribose)polymerase (PARP), an enzyme that is activated by DNA strand
breaks and involved in their repair (Shall and de Murcia 2000), blocks
the induction by ionizing radiation of an adaptive response that prevents
radiation-induced clastogenic effects in mammalian cells (Shadley and
Wolff 1987; Stecca and Gerber 1998; Miura 2004). Inhibition of PARP
also eliminates the reduction in frequency of neoplastic transformation
that occurs by radiation hormesis in mammalian cells (Pant et al. 2003).
Research in a simple whole-animal model, the nematode worm
Caenorhabditis elegans, demonstrates the existence of mutants altered in
hormetic responses. Exposure to low doses of stressors (e.g., heat, ioniz-
ing radiation, or hyperbaric oxygen) leads to increased longevity in wild-
type worms (Cypser and Johnson 2003). Conserved genes of the
insulin/insulin-like signaling pathway, including daf-16 and daf-18, are
involved in lifespan determination and are required for hormetic life
extension (Cypser and Johnson 2003; Cypser et al. 2006). The dauer stage
in Caenorhabditis is resistant to unfavorable environmental conditions and
occurs as an alternative to continued development to the adult stage.
Mutations in daf-16, daf-18, or daf-12, which block the formation of
dauers, also block the hormetic response to heat stress (Cypser and
Johnson 2003).
BIPHASIC CURVES IN HETEROGENEOUS POPULATIONS
Sensitive subgroups in populations pose difficult challenges for risk
assessment (Thayer et al. 2005, 2006). Differences in chemical responses
owing to age, health status, and such genetic attributes as enzyme poly-
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morphisms need to be considered under any dose-response model, but
the biphasic curves of hormesis present unique challenges not encoun-
tered with monotonic responses. Figure 3 shows hormesis in a typical
population and a sensitive subpopulation. The sensitive subgroup repre-
sents a small part of the population in which the adverse effect occurs at
a lower dosage. Given the differences in sensitivity, most doses that are
hormetic for the population as a whole would be toxic for the sensitive
group. Such curves raise questions not seen with monotonic curves, in
that part of the population would benefit in the hormetic zone, whereas
another part would be harmed. If the dose-response were described by a
threshold or LNT model, subpopulations can differ in the extent of
harm, or even the presence or absence of harm, but they would not expe-
rience the opposite outcomes of harm versus benefit.
An optimal solution given these curves is elusive, even if one assumes
that the NOAEL in both subpopulations can be measured with precision.
In the spectrum of possible solutions, one pole is strict adherence to the
aphorism “do no harm,” such that protection of the most sensitive ele-
ment of the population is the highest priority. At the opposite pole is a
course of utilitarian ethics, striving for the greatest good for the greatest
number. To do so, one might contemplate using smaller safety factors
below the NOAEL, and this may benefit the typical population (Gaylor
1998). The first pole sacrifices the hormetic benefit to the majority,
whereas the second buys a lower incidence of adverse effect for the pop-
ulation as a whole by risking harm in the sensitive subpopulation.
Intermediates between the poles can be envisioned, just as they can in
other biomedical situations. In clinical trials, for example, a balance is
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subpopulation with greater toxicant susceptibility. The response is an adverse effect occurring at a lower
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sought between heeding warning signals and terminating a trial when
there is evidence of adverse effects, but yet not so quickly that premature
termination unnecessarily sacrifices the potential benefit of the study.
The principle of nonmaleficence lends itself to a course closer to early
termination in clinical trials and to protection of sensitive subgroups in
heterogeneous populations.
Hormesis poses an especially difficult challenge in the case just con-
sidered (Figure 3) because the zone that is hormetic to both subpopula-
tions is small, and its delineation may never be attainable. Figure 4 shows
curves for populations differing in the extent of sensitivity of the sensitive
subgroup. Figure 4A shows greater overlap between the hormetic zones
of the two subpopulations. If one were to attempt to regulate to the
hormetic zone, the challenge in this case would be to find a position suf-
ficiently to the left to ensure that the exposure is in the hormetic zone for
the sensitive subpopulation while remaining in the hormetic zone for the
typical population. This is the scenario on which Cook and Calabrese
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FIGURE 4. Dose response curves showing greater and smaller differences between a typical popula-
tion and a small subpopulation with higher susceptibility to adverse effects.
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(2006) suggested that exposures below the NOAEL for the sensitive pop-
ulation can be beneficial for the entire population. Figure 4B, showing a
large difference between subgroups, raises interesting questions about
how to respond when protecting the sensitive group becomes increasing-
ly difficult, but it falls largely outside the scope of a perspective on horme-
sis because it poses comparable difficulty under any dose-response model.
The distribution of benefit and harm in different parts of a popula-
tion would need to be considered if the hormesis model enters into risk
management. Ethical considerations, especially the primacy of non-
maleficence, place a high priority on protecting sensitive groups. If one
looks beyond public health to environmental policy, a parallel problem
exists, as heterogeneity in susceptibility among species is rarely known in
a broad sense. Ecological effects of low doses and effects on sensitive
species warrant continued consideration.
COMPLICATIONS OF HORMESIS
The diverse manifestations of hormesis introduce variation into how
one encounters it, and the mechanistic complexity of the phenomenon
can lead to complications of interpretation.
Some hormetic responses do not yield typical hormetic curves
In order to observe the J-shaped curve of hormesis, responses need to
be measurable both above and below background levels (Calabrese and
Baldwin 2001b). If an effect occurs at a low spontaneous frequency, such
as some tumors, one may not be able to measure a decrease in its fre-
quency. An agent that induces the effect at high dose would therefore not
be seen to reduce its incidence at low doses, because the control inci-
dence is zero or near to zero. In this instance, the measurable curve will
appear to fit a threshold model.
Some adaptive responses may not reveal hormetic curves for mecha-
nistic reasons. One of the mechanisms of hormesis is inducible repair of
genetic damage. Besides removing damage induced by environmental
agents, repair mechanisms remove damage caused by the inherent error
rates of biological processes, endogenous stressors, and spontaneous
DNA degradation (Lindahl 1993). Curves measuring damage can differ
in form depending on whether spontaneous damage is a significant con-
tributor to the total damage. If the signal is a premutational lesion that is
infrequent or absent spontaneously but likely to cause mutation if unre-
paired, the inducible response can repair the lesions and reduce the
effect of a subsequent exposure, but it may not yield a J-shaped curve
because there is little or no spontaneous damage to remove. In contrast,
if the inducing agent induces a kind of damage that is common sponta-
neously and contributes to the background level of the effect, the adap-
Perspective on hormesis
35
35
Hoffmann: Perspective on hormesis
Published by ScholarWorks@UMass Amherst, 2014
tive response can reduce the damage below the spontaneous level, thus
giving a nonmonotonic curve (Kodell 2001). It is therefore not surprising
that adaptive responses (Demple and Halbrook 1983; Davies et al. 1995;
Wiese et al. 1995; Chen et al. 2006a) and biphasic curves (Davies et al.
1995; Caporossi et al. 2003) have both been reported for hydrogen per-
oxide and other agents that induce oxidative DNA damage. These find-
ings are consistent with other studies showing biphasic curves for the
induction of lipid peroxidation by the superoxide radical (McCord 2002)
and protection or exacerbation of cardiac ischemia-reperfusion injury by
superoxide (McCord and Edeas 2005).
Hormetic curves may not be observed if background levels of expo-
sure are already in the toxic zone. Although hormetic responses may
occur in such cases at exposures smaller than control levels of exposure,
they would be irrelevant under the prevailing conditions. Some examples
cited as arguments against hormesis (Axelrod et al. 2004), such as human
lead exposures, may fit this category, and they illustrate the need for
refined exposure assessments (Davis and Farland 1998). Agents that
mimic endogenous substances can pose a similar problem for certain
endpoints if the endogenous substance is a risk factor, such as estrogens
and breast cancer (vom Saal and Sheehan 1998).
Dose dependence of the induction of stress responses
The induction of a stress response may show evidence of hormesis
independently of whether the response itself is demonstrably biphasic.
Adaptive responses are absent without a conditioning exposure and are
induced by low doses. There is evidence in some cases that the induction
is biphasic (Feinendegen 2005). When an x-ray exposure makes human
lymphocytes less susceptible to the induction of chromosomal damage by
a second exposure, the protective effect is most prominent with small
priming doses (~10 mGy), decreases with dose, and is no longer detected
at doses over ~200 mGy (Shadley and Wolff 1987). Similarly, the induc-
tion of an adaptive response using growth as an endpoint in HE22 human
embryonic cells showed a peak at 13 cGy (Ishii and Watanabe 1996).
Despite the evidence that adapting exposures may occur within a window
of dosage, thus being hormetic rather than monotonic, it would be pre-
mature to generalize that conditioning exposures uniformly fit this pat-
tern. Doses spanning a broad range have been observed to be equally
effective in inducing an adaptive response in other systems, including
radiation-induced micronuclei in human fibroblasts (Broome et al. 2002)
and the pKZ1 assay for chromosomal inversions in mice (Day et al. 2007).
Systems that differ in cellular targets, endpoints, mechanisms, and tem-
poral considerations apparently vary in the dose-dependence of induc-
tion of adaptive responses (Wolff 1998; Broome et al. 2002).
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Interactions among agents
Toxicologists have long recognized that biological effects need not be
additive, and interactions among agents can take diverse forms. One
agent may potentiate another or, if both are themselves active, their com-
bined effects can be synergistic (Hoffmann et al. 2007). Alternatively, the
interactions can be antagonistic, such that one agent diminishes the
effects of another. The latter includes antimutagenic and anticarcino-
genic effects (Hartman and Shankel 1990; De Flora and Ferguson 2005).
Such interactions are of interest for their potential application in the pre-
vention of cancer or other disorders (De Flora and Ferguson 2005), but
caution is required because the same agent that is protective under one
set of conditions may be mutagenic, carcinogenic, or enhance the
adverse activity of other agents under other conditions (Zeiger 2003;
Hoffmann et al. 2007).
Interactions among agents are a mystery with respect to hormesis. If
two agents are in the hormetic zone, do they combine to give a toxic
effect? Alternatively, is there a hormetic effect equal to or greater than
the sum of the separate hormetic effects? There is no basis for answering
such questions at present, yet assumptions about the answer have figured
into arguments against hormesis, based on speculation that multiple
chemicals in the hormetic zone would be equivalent to a toxic exposure
(Axelrod et al. 2004; Thayer et al. 2005; Shrader-Frechette 2008).
Alternatively, one might speculate that hormetic interactions may be con-
strained by the plasticity of biological systems that gives hormesis similar
quantitative features in diverse systems (Calabrese 2005a; Calabrese and
Blain 2005; Calabrese 2008a). Assumptions and speculation are insuffi-
cient; potential interactions among agents with respect to hormesis need
to be evaluated scientifically, and doing so will not be easy.
Nature of the subhormetic zone
Shapes of hormetic curves may be more varied than the typical U and
J. At very low doses, the hormetic zone of a J or inverted-U curve must
return to the background level, as the effect must be zero at the ordinate.
A low, nonzero dose induces the hormetic response, and this raises the
question as to what happens in the subhormetic zone. Figure 5A shows a
typical J-shaped hormetic curve, pointing out the unknown nature of the
subhormetic zone. If the doses that induce hormesis are so low that they
cause no effect in themselves, one might expect such an idealized J or
inverted-U curve. Alternatively, if the hormesis-inducing dose causes a
low level of damage, one should expect to see curves more complex than
the simple J or inverted U. An expanding triphasic wave, shown in Figure
5B, would make sense as a dose-response relationship for an agent that
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causes damage and an inducible repair response at low dose. One might
think that such a hypothetical possibility could not be observed because
it is hard enough to measure effects in the hormetic zone, let alone the
subhormetic zone. However, there is evidence that exquisitely sensitive
assays can offer insight into the nature of the subhormetic zone.
The pKZ1 transgenic mouse assay was used to study the induction of
inversions that arise by SICR at x ray doses from 1 μGy to 2 Gy (Hooker
et al. 2004; Sykes et al. 2006). There was induction of inversions at ultra-
low doses, a reduction below the spontaneous frequency at low doses, and
a larger induction of inversions at higher doses. At the lowest effective
doses, where few cells experience damage, effects may be mediated by
bystander effects, triggered in nonirradiated cells by signaling from
neighboring cells that experienced damage (Sykes et al. 2006). Hooker et
al. (2004) offered a speculative but credible interpretation of the three
G. R. Hoffmann
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FIGURE 5. Hormesis and the subhormetic zone: (A) Typical hormetic J-shaped curve indicating the
unknown nature of the subhormetic zone. (B) Hypothetical triphasic curve that may occur if an
agent causes damage and an inducible repair response at low dose.
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phases of the curve. At ultra-low doses (~10 μGy), DNA damage leads to
an increase in inversions. At low doses (1-10 mGy), there is hormesis. The
induced DNA damage either directly or indirectly triggers a decrease in
repair of double-strand breaks by nonhomologous end joining; the result
may be an increase in apoptosis that could prevent carcinogenesis
(Hooker et al. 2004). At doses >100 mGy, there is induction of SICR that
causes inversions but repairs large amounts of induced DNA damage
(Hooker et al. 2004). The results clearly do not fit LNT, and they resem-
ble the hypothetical triphasic curve.
Temporal component of hormetic responses
A temporal component is often underestimated or overlooked in stud-
ies of hormesis, yet it can be critical if hormesis is the result of an initial dis-
ruption of homeostasis (Calabrese and Baldwin 2001b). If hormesis
depends on the induction of an adaptive response, one might expect to see
no immediate hormetic response at the time of exposure, an increase in
the hormetic response after the required time for induction, a maximum
expression of hormesis, and then a return to the base level of response
(Calabrese and Baldwin 2002a; Calabrese 2005c, 2008a; Feinendegen 2005;
Calabrese et al. 2007). Studies of the time course of hormetic effects are
limited, yet experimental evidence supports the basic pattern illustrated in
Figure 6, which provides a context for the discussion that follows.
Time is typically required after a conditioning exposure for the full
expression of an adaptive response that depends on protein synthesis
(Stecca and Gerber 1998; Wolff 1998). For example, deToledo and Azzam
(2006) found that the protective effect conferred by a moderate dose of
γ-rays at a low dose rate (0.5 Gy at 0.002 Gy/min) against the induction of
micronuclei by a higher dose and dose rate (4 Gy at 1.8 Gy/min) in cul-
tured human fibroblasts is greater if there is a delay between the condi-
tioning and challenging doses. The adaptive response that makes divid-
ing human lymphocytes that were exposed to low doses of x rays (~5-10
mGy) less susceptible to the induction of chromatid breakage by a subse-
quent high dose (Shadley and Wolff 1987; Shadley et al. 1987) requires
about 4-6 h for induction to occur. The induced state disappears with
time (Wolff 1998) after persisting through several cell divisions (Shadley
and Wolff 1987; Shadley et al. 1987). The observation of hormesis in the
cell transformation assay of Redpath and colleagues also depends on
delayed plating to allow for postirradiation gene expression (Redpath et
al. 2003a). The time-dependence of hormesis undoubtedly applies to
chemicals as well as radiation. For example, a study of the cytotoxicity of
chlorpromazine in mouse neuroblastoma cells showed toxicity at 30 μM
and hormesis at 3 μM. The hormetic effect was not evident at 24 h, in that
the response was 60% of the control, but it was 135% at 48h and declined
to 120% at 72h (Andres et al. 1999). Other studies similarly show that the
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induction of adaptive responses is time-dependent and transient, and
they suggest that the time course and absolute doses differ among cell
types (Ishii and Watanabe 1996; Park et al. 1999).
Taken together, the evidence suggests that if one measures biological
effects too early, the response may appear to fit a threshold or linear
model rather than show hormesis because insufficient time has elapsed
for the requisite gene expression for an adaptive response. If one makes
measurements too late, the system may have already returned from the
induced state to the ground state. Accounting for temporal factors is a
complication that affects the ability to observe hormesis in laboratory
studies. The time dimension is also relevant to nonlaboratory conditions
and would have to be considered in any attempts to include hormesis in
hazard assessment.
Genetic dissection of hormesis
There is evidence of hormesis for many biological endpoints, agents,
and species but little evidence on whether there are specific effects,
agents, or genotypes for which hormesis does not occur. Mutation has
been a useful tool for dissecting biological phenomena, such as the use of
repair-deficient mutants in the study of DNA repair. It is of great interest
to identify hormesis-minus mutants or other mutants with altered
hormetic responses in model organisms.
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FIGURE 6. Time course of hormesis: The curves show no immediate hormetic effect, an increasing
hormetic response after the requisite time for induction, and a maximum hormetic effect followed
by a return to the ground state. The figure is adapted from Calabrese et al. 2007.
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In the NCI drug-screening database, 11 of 13 yeast strains carry known
alterations that affect DNA repair or cell-cycle progression, and all display
hormesis (Calabrese et al. 2006, 2008). Finding hormesis-minus mutants is
not easy because the phenotypic effect is quantitative, subtle, and typical-
ly small. Exploring gene expression associated with stress responses is apt
to be more fruitful, and genetic functions required for adaptive responses
(i.e., conditioning hormesis) have been identified in several biological sys-
tems (Shadley and Wolff 1987; Volkert 1988; Shevell et al. 1990; Stecca and
Gerber 1998; Kleibl 2002; Cypser and Johnson 2003; Pant et al. 2003). The
research in nematode worms discussed earlier (Cypser and Johnson 2003;
Cypser et al. 2006), as well as that in other model organisms, offers great
promise for elucidating the genetic underpinnings of hormesis in specific
genetic systems. Nevertheless, gene functions central to the hormetic
response can be elusive owing to the multiplicity of mechanisms that are
likely to be involved. The genetic dissection of hormesis remains a difficult
and important challenge for the future.
Nontargeted damage, bystander effects and genetic instability
Nontargeted damage, including bystander effects and genomic insta-
bility, raise interesting questions about risks of low-dose exposures. Strong
evidence indicates that cells that are not themselves irradiated may expe-
rience cytotoxicity, apoptosis, chromosome aberrations, and other bio-
logical effects if they receive signals from other cells that have been
exposed to ionizing radiation (Zhou et al. 2001; Morgan 2002, 2003a,
2003b, 2003c; Azzam and Little 2004; Mothersill and Seymour 2004a,
2004b, 2006a, 2006b; Belyakov et al. 2005; Morgan and Sowa 2005).
These nontargeted effects, commonly called bystander effects, may be
mediated by diffusible messengers from exposed cells or by direct cellu-
lar contact. At high-doses, bystander effects are apt to be eclipsed by
direct effects of irradiation, but they can be important at low doses
(Mothersill and Seymour 2006a). There is no reason to think that
bystander effects are unique to radiation, yet such effects are technically
difficult to detect and quantify for chemical exposures (Mothersill and
Seymour 2004a, 2004b). Genomic instability is a special case of nontar-
geted damage in which biological effects continue to arise in the proge-
ny of affected cells (Morgan 2003a, 2003b; Azzam and Little 2004;
Mothersill and Seymour 2004a, 2004b, 2006a).
A concern about bystander effects and induced genetic instability is
that they may cause previously unpredicted adverse effects at low doses.
Because they imply a larger target, it has been suggested that adverse
effects in nontargeted cells may manifest themselves as supralinear dose
responses—deviations from LNT opposite to those expected for horme-
sis, thus implying greater risk (Brenner et al. 2001, 2003; Zhou et al. 2001;
Morgan 2002). Adaptive responses and bystander effects have been
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described as conflicting phenomena because the former reduce risk at
low doses, whereas the latter may increase it (Zhou et al. 2003). The com-
plexity is increased by the fact that the two effects are apparently not inde-
pendent of one another, in that low doses of x rays given before an expo-
sure of mammalian cells to α particles decreased the bystander mutagen-
esis (Zhou et al. 2003). 
Strong evidence indicates that low-dose irradiation of nontrans-
formed cells enhances apoptosis in nearby transformed cells (Bauer
2007; Portess et al. 2007). Portess et al. (2007) used a coculture system to
explore the mechanism underlying this bystander effect by which normal
cells selectively eliminate transformed cells. The intercellular induction
of apoptosis is modulated by reactive oxygen and nitrogen species,
involves transforming growth factor type beta (TGF-β), and does not
require cell-to-cell contact (Bauer 2007; Portess et al. 2007). Superoxide
anion plays a central role in the signaling (Bauer 2007). Various normal
cell types (e.g., fibroblasts, epithelial cells, endothelial cells, monocytes, B
cells) can serve as effectors, and the occurrence of induced apoptosis is
strictly dependent on the transformed state of the target cells (Bauer
2007). Irradiation of nontransformed cells with doses as low as 2 mGy γ-
rays or 0.29 mGy α-particles stimulated the induction of apoptosis in unir-
radiated transformed cells, an effect that increased with dose to a plateau
at ≥50 mGy γ or 25 mGy α (Portess et al. 2007).
To reach conclusions on risk, one needs a better sense of the dose-
response relationships for the induction of bystander effects, how they are
propagated, and most importantly, the balance between different ele-
ments of the bystander response. It is unclear how bystander effects affect
carcinogenesis because bystander mutagenesis or transformation may
increase risk while increased cell death may decrease risk (Friedl and
Rühm 2006). Bystander effects include diverse endpoints, including muta-
tions, chromosome aberrations, micronuclei, neoplastic transformation,
reduced survival, and apoptosis. It is possible that increases in chromo-
some aberrations, mutagenesis, or transformation in the bystander popu-
lation are overshadowed by increased cell death, repair capacity, or other
protective factors. An evolutionary perspective makes protective effects
seem likely but, like the proposition of heightened risk by bystander
effects, this is speculative. There is much to learn about the implications
of nontargeted damage for the interpretation of low-dose effects.
CONCLUSIONS
This perspective on hormesis supports the following conclusions:
1 Growing evidence supports the reality and common occurrence of
hormesis.
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2 The hormesis concept merits empirical evaluation and refinement
independently of whether it is assimilated into policy on toxic sub-
stances.
3 It would be premature to regulate to the hormetic zone for chemical
exposures now. How hormesis figures into policy needs to be revisited
as risk assessment improves.
4 Using hormesis for regulatory purposes would require better under-
standing of the positions of the toxic and hormetic zones for diverse
endpoints, tissues, individuals, and species.
5 Biphasic dose responses raise challenging ethical questions regarding
sensitive subpopulations.
6 Ecological effects of low doses and differences among species with
respect to hormesis warrant continued investigation. 
7 Effective exploitation of hormesis in medicine and agriculture is like-
ly to precede its use in toxicologic risk assessment. 
8 Deeper understanding of stress responses can stimulate medical and
technological advances. 
9 The hormesis concept has important implications for antimicrobial
and cancer therapy. 
10 Better understanding of hormesis can foster effective public health
and environmental policies.
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